Document:

ex_136246.htm

Exhibit 10.12

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

 

SUPPLIER AGREEMENT

 

This Supplier Agreement (this “Agreement”) is entered into, effective as of January 1, 2019 (the “Effective Date”), by and between Millipore (U.K.) Ltd., an English company with its principal place of business at Suite 21, Building 6, Croxley Green Business Park, Watford, Hertfordshire WD18 8YH, UK (“Merck”), and Oxford Immunotec Limited, an English company with its principal place of business at 94C Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, UK (“Oxford” or “Customer”)). As used in this Agreement, “Party” means Merck or Customer, and “Parties” means, collectively, Merck and Customer.

 

WITNESSETH:

 

WHEREAS Merck is in the business of manufacturing, distributing and selling life science consumables, instrumentation and other products; and

 

WHEREAS Customer is interested in purchasing and utilizing certain Merck products, all in accordance with the terms of this Agreement.

 

NOW, THEREFORE, in consideration of the mutual promises and covenants set forth herein, the Parties hereto agree as follows:

 

	
			1. 

				
			DEFINITIONS

			

 

	 	
			1.1.

				
			“Additional Orders” has the meaning set forth in Section 4.3.

			

 

	 	
			1.2.

				
			“Affiliate” means, with respect to a Party, any corporation, company, partnership, joint venture and/or firm that controls, is controlled by or is under common control with such Party. As used in this definition, “control” means (a) in the case of a corporate entity, direct or indirect ownership of more than fifty percent (50%) of the stock or shares having the right to vote for the election of directors, and (b) in the case of a non-corporate entity, the direct or indirect power to manage, direct or cause the direction of the management and policies of the non-corporate entity or the power to elect more than fifty percent (50%) of the members of the governing body of such non-corporate entity.

			

 

	 	
			1.3.

				
			“Agreement” has the meaning set forth in the preamble of this Agreement.

			

 

	 	
			1.4.

				
			“Binding Forecast” has the meaning set forth in Section 4.1.

			

 

	 	
			1.5.

				
			“Commercial Forecast” has the meaning set forth in Section 4.1.

			

 

-1-

 

 

	 	
			1.6.

				
			“Confidential Information” has the meaning set forth in Section 6.1.

			

 

	 	
			1.7.

				
			“Customer” has the meaning set forth in the preamble of this Agreement.

			

 

	 	
			1.8.

				
			“Customer Indemnified Party” has the meaning set forth in Section 7.2.

			

 

	 	
			1.9.

				
			“Discloser” has the meaning set forth in Section 6.1.

			

 

	 	
			1.10.

				
			“Effective Change Date” has the meaning set forth in Section 4.7(a).

			

 

	 	
			1.11.

				
			“Effective Date” has the meaning set forth in the preamble of this Agreement.

			

 

	 	
			1.12.

				
			“Federal healthcare programs” has the meaning set forth in Section 8.4.

			

 

	 	
			1.13.

				
			“Finished Product” has the meaning set forth in Section 7.1(d).

			

 

	 	
			1.14.

				
			“Force Majeure Event” has the meaning set forth in Section 11.6.

			

 

	 	
			1.15.

				
			“Indemnified Party” has the meaning set forth in Section 7.3.

			

 

	 	
			1.16.

				
			“Indemnifying Party” has the meaning set forth in Section 7.3.

			

 

	 	
			1.17.

				
			“List Price” has the meaning set forth in Section 2.1.

			

 

	 	
			1.18.

				
			“Losses” has the meaning set forth in Section 7.1.

			

 

	 	
			1.19.

				
			“Material Change” has the meaning set forth in Section 4.7.

			

 

	 	
			1.20.

				
			“Merck” has the meaning set forth in the preamble of this Agreement.

			

 

	 	
			1.21.

				
			“Merck Indemnified Party” has the meaning set forth in Section 7.1.

			

 

	 	
			1.22.

				
			“Non-Binding Forecast” has the meaning set forth in Section 4.1.

			

 

	 	
			1.23.

				
			“Non-Conforming Additional Orders” has the meaning set forth in Section 4.3.

			

 

	 	
			1.24.

				
			“Order Date” or “Order Dates” have the meaning set forth in Section 4.2.

			

 

	 	
			1.25.

				
			“Oxford” has the meaning set forth in the preamble of this Agreement.

			

 

	 	
			1.26.

				
			“Party” or “Parties” has the meaning set forth in the preamble of this Agreement.

			

 

	 	
			1.27.

				
			“Price” has the meaning set forth in Section 2.1.

			

 

	 	
			1.28.

				
			“Product(s)” has the meaning set forth in Section 2.1.

			

 

	 	
			1.29.

				
			“Product Warranty” has the meaning set forth in Section 8.1(A).

			

 

	 	
			1.30.

				
			“Purchase Order” has the meaning set forth in Section 4.2.

			

 

	 	
			1.31.

				
			“Recipient” has the meaning set forth in Section 6.1.

			

 

-2-

 

 

	 	
			1.32.

				
			“Site” has the meaning set forth in Section 2.2.

			

 

	 	
			1.33.

				
			“Specifications” means the written specifications for each Product as set forth on Exhibit B attached hereto.

			

 

	 	
			1.34.

				
			“Taxes” has the meaning set forth in Section 3.2.

			

 

	 	
			1.35.

				
			“Term” has the meaning set forth in Section 9.1.

			

 

	 	
			1.36.

				
			“Termination for Convenience” has the meaning set forth in Section 9.2.

			

 

	 	
			1.37.

				
			“Third Party” means any person or entity other than Merck, Customer or their respective Affiliates.

			

 

	 	
			1.38.

				
			“Warranty Period” has the meaning set forth in Section 8.1(A).

			

 

	
			2. 

				
			PRODUCTS 

			

 

Products. During the Term, and subject to the covenants, terms and conditions of this Agreement, Customer agrees to buy from Merck, and Merck agrees to sell to Customer, the Merck products set forth in Exhibit A attached to this Agreement (the “Products”) at the prices for such Products set forth on Exhibit A as such prices may be changed in accordance with the terms of this Agreement (the “Price”). The list of Products to be included in Exhibit A may be modified at any time during the Term by mutual written agreement of the Parties.

 

	
			3. 

				
			PRICING

			

 

	 	
			3.1.

				
			Price; Payment Terms. For each Product purchased pursuant to this Agreement, Merck shall invoice Customer, and Customer shall pay Merck, the Price. Merck shall invoice Customer upon each shipment of Product, and Customer shall pay Merck in full within thirty (30) days of invoice date. An interest charge equal to [***]% per month ([***]% per year) will be added to invoices outstanding beyond forty-five (45) days of the invoice date. In the event Customer’s account is overdue for a period of more than sixty (60) days or Customer otherwise has an unsatisfactory credit or payment record, Merck reserves the right in its reasonable discretion to (a) require C.O.D. payment terms, (b) refuse to ship any accepted Purchase Order until overdue accounts are paid in full and/or (c) increase the Price.

			

 

	 	
			3.2.

				
			Taxes. All amounts to be paid by Customer are exclusive of any applicable taxes, duties, customs, imports, levies or any other fee of any nature imposed by any federal, state or local government authority including, but not limited to, any VAT, excise and sales taxes (collectively “Taxes”), which Taxes will be payable by Customer. In the event Merck is required to prepay any such Taxes, Customer will reimburse Merck within thirty (30) days after receipt of an invoice from Merck.

			

 

-3-

 

 

	 	
			3.3.

				
			Packaging Costs. All Prices are based upon Customer Purchase Orders in standard commercial packaging. Any Customer requests for non-standard packaging may result in additional charges.

			

 

	 	
			3.4.

				
			Adjustment to Price. Once per calendar year during the Term, but no earlier than the first anniversary of the Effective Date, Merck may increase the Price as further set forth below by providing Customer thirty (30) days prior written notice. Any such Price increase shall only be effective as to Purchase Orders placed after the effective date of the Price increase and shall not exceed the greater of: (i) [***] ([***]%) percent; or (ii) the UK RPIX for the preceding twelve (12) months (UK Retail Price Index excluding mortgage interest – see Office of National Statistics at http://www.ons.gov.uk/ons/key-figures/index.html. Merck shall review Customer’s Product purchases in connection with its annual Price adjustment described above and if such Product purchases are [***] percent ([***]%) or more lower during the most recently completed calendar year than Product purchases in the prior calendar year, notwithstanding the foregoing, Merck reserves the right to increase Price in excess of the limits set forth above, to a maximum of [***] percent ([***]%).

			

 

	
			4. 

				
			FORECASTS; ORDERING; PRODUCT CHANGES

			

 

	 	
			4.1.

				
			Forecasts. No later than October 1 of each calendar year during the Term, Oxford shall provide Merck with a non-binding, written, annual forecast of its intended Product purchases for the forthcoming calendar year (the “Commercial Forecast”). After delivery of the initial Commercial Forecast for each calendar year, Customer shall deliver to Merck an updated Commercial Forecast on a calendar quarterly basis, which update shall include the next successive calendar quarter added to the last period of the previous Commercial Forecast.

			

 

	 	
			4.2.

				
			Purchase Orders. No later than January 1, April 1, July 1 and October 1 (each an “Order Date” and collectively the “Order Dates”) of each calendar year during the Term, Oxford shall provide Merck with its written, binding and irrevocable purchase order (each individually a “Purchase Order” and collectively the “Purchase Orders”) for Products for the next calendar quarter (e.g., Purchase Order submitted on January 1 will correspond to the calendar quarter beginning on April 1). In the event Customer does not require Products in a given calendar quarter and thus does not wish to order any, Customer shall notify Merck of same in writing on the applicable Order Date. Each Purchase Order shall specify the following: (a) the quantity and description of each Product ordered, with a minimum Purchase Order quantity of [***] Products per Purchase Order (assuming Oxford is ordering Product for such calendar quarter); (b) the address of the delivery site; (c) the requested delivery date(s), which delivery date shall not be less than eight (8) weeks from the date of the Purchase Order. In the event the Purchase Order exceeds [***] Products, Merck may, in its sole discretion, extend the delivery date an additional seven (7) weeks for a total of fifteen (15) weeks from the date of the Purchase Order. Merck shall promptly confirm each Purchase Order in writing which shall be deemed its acceptance of such Purchase Order in accordance with the terms and conditions of this Agreement. For the purposes of the provisions in this Agreement concerning confirmation and acceptance of Purchase Orders, “promptly” shall mean no later than ten (10) working days following Merck’s receipt of the applicable Purchase Order. In the event Customer identifies an error in Merck’s confirmation and acceptance of a Purchase Order, Merck will promptly correct such error after receipt of written notice from Customer. Merck is not obliged to deliver, and Customer is not obliged to purchase, any Products other than those set forth on Purchase Orders that have been accepted by Merck. Purchase Orders may be placed on Customer’s Purchase Order form, but any terms on such form that are in addition to or different from the terms of this Agreement will be of no force or effect.

			

 

-4-

 

 

	 	
			4.3.

				
			Additional Orders. Merck shall promptly confirm in writing and thereby accept Purchase Orders in addition to those placed by Customer on or by the Order Dates (“Additional Orders”), except when: (a) such Additional Orders exceed [***] Products; (b) Oxford has placed more than two (2) Additional Orders during any calendar quarter; or (c) cumulative Purchase Orders in any calendar year during the Term exceed [***] Products (collectively, the “Non-Conforming Additional Orders”). In each case Merck may, in its sole discretion, promptly confirm in writing and thereby accept such Non-Conforming Additional Orders and/or indicate in such written confirmation different delivery dates for the Products set forth in such Non-Conforming Additional Orders; provided, however, that such dates shall be within a commercially reasonable timeframe. To the extent any such Non-Conforming Additional Orders are confirmed in writing and thereby accepted by Merck, it shall be obligated to fulfill the applicable Non-Conforming Additional Orders within the delivery date indicated in the applicable written confirmation.

			

 

	 	
			4.4.

				
			No Order Cancellation. Purchase Orders may not be cancelled under any circumstances, unless otherwise agreed in writing by the Parties.

			

 

	 	
			4.5.

				
			Rescheduling of Orders. Oxford may reschedule the delivery dates of any Purchase Order at any time prior to the shipment date by providing reasonable advance written notice to Merck, provided that the newly rescheduled delivery date is no later than thirty (30) days after the original delivery date. Merck shall use commercially reasonable efforts to accommodate such rescheduling.

			

 

-5-

 

 

	 	
			4.6.

				
			Product Acceptance and Returns.

			

 

	 	
			(a)

				
			Acceptance. Oxford shall be responsible for inspecting all Products shipped hereunder prior to acceptance; provided however, that if Oxford shall not have given Merck written notice of rejection within thirty (30) days following shipment to Oxford, the Products shall be deemed to have been accepted by Oxford. Acceptance shall not be deemed to be a waiver or limitation of Merck’s obligations pursuant to this Agreement (or any breach thereof), including those obligations with respect to Merck’s Product warranty and Merck’s duty to indemnify Oxford as set forth below.

			

 

	 	
			(b)

				
			Returns. No Product shipped under this Agreement may be returned without the express prior written authorization of Merck, which may be withheld in Merck’s reasonable discretion. Merck shall pay any shipping costs associated with returning rejected Products. At Merck’s reasonable discretion, and as Oxford’s sole remedy, Merck shall promptly either refund or replace any Products rejected by Oxford and confirmed by Merck.

			

 

	 	
			4.7.

				
			Product Change. In the event of a change in the manufacturing, form, fit, function, testing or documentation of any Product, that could reasonably be expected to materially impact the performance or Specifications of the Product (a “Material Change”), Merck shall use best efforts to notify Oxford of such changes at least six (6) months prior to the Effective Change Date. Notwithstanding the foregoing, on rare occasions Merck may not be able to provide at least six (6) months advance notice due to unplanned situations, including without limitation, interruptions in Merck’s supply chain. In such situations, Merck shall provide as much advance notice as reasonably possible of the applicable Effective Change Date. If Merck provides less than six (6) months’ notice of a Material Change and such short notice in Customer’s reasonable discretion will impact Customer’s supply needs, Customer shall have the right to adjust or cancel a Purchase Order without penalty. Upon receipt of such notification, Oxford shall use commercially reasonable efforts to obtain regulatory market approval for such change (if such approval is necessary and Oxford decides, in its reasonable discretion, to continue utilizing the Products) prior to the Effective Change Date. Merck shall use (i) commercially reasonable efforts to support Oxford’s regulatory market approval efforts which may include providing Oxford with necessary Product information and (ii) best efforts to supply Oxford with the Product, as manufactured prior to the Material Change, until the earlier of (a) such time as Oxford has validated or obtained regulatory market approval for the Product which includes the Material Change or (b) Merck is no longer able to produce the Product prior to the Material Change. Any such Product information shall be considered “Confidential Information” hereunder.

			

 

	 	
			4.8.

				
			Inspection and Testing. Merck shall inspect and test all Products prior to shipment to Oxford in accordance with Merck’s standard quality control procedures. Merck shall provide a certificate of quality/analysis upon Oxford’s written request in the form attached hereto as Exhibit B.

			

 

-6-

 

 

	 	
			4.9.

				
			Right to Audit. Merck shall, upon receiving reasonable prior notice from Oxford, during normal business hours on a mutually agreed upon date and time, permit one (1) or more individual(s) from Oxford, regulatory agencies and/or notified bodies to conduct inspections and audits of Merck’s facilities that produce the Products, provided that Oxford’s representatives comply with Merck’s visitation policies provided to Customer in advance and the provisions regarding Confidentiality set forth in Section 6 herein.

			

 

	 	
			4.10.

				
			Labelling. Special packaging and labeling requests may result in extra charges.

			

 

	
			5. 

				
			SHIPPING AND DELIVERY

			

 

	 	
			5.1.

				
			Shipping. All shipments of Product will be made FCA (Merck’s distribution center) Incoterms® 2010. Title will pass to Customer when the Product leaves Merck’s point of distribution. Shipments will be made by standard shipping delivery service, with the cost of freight paid by Merck and included in the Price.

			

 

	 	
			5.2.

				
			Delivery. If Merck is unable to meet the delivery dates set forth in a confirmed Purchase Order, Merck shall promptly notify Customer of the delay after it is made known to Merck. If in Customer’s reasonable discretion such delay will impact Customer’s supply needs, Customer shall have the right to adjust or cancel a Purchase Order without penalty upon receipt of Merck’s prior written consent, which shall not be unreasonably withheld.

			

 

	
			6. 

				
			CONFIDENTIALITY 

			

 

	 	
			6.1.

				
			Definition. “Confidential Information” means any confidential scientific, technical, financial or business information of a Party (“Discloser”) in whatever form (written, oral or visual) which is treated by such Party as confidential and is provided to the other Party under this Agreement (“Recipient”). Confidential Information of Merck includes, but is not limited to, Specifications, Prices, formulae, processes, records, techniques, know-how and other proprietary information.

			

 

	 	
			6.2.

				
			Obligations. Recipient agrees (a) to keep confidential the Confidential Information of Discloser and the terms of this Agreement, (b) not to disclose Discloser’s Confidential Information to any Third Party without the prior written consent of Discloser, and (c) to use such Confidential Information only as necessary to fulfill its obligations or in the reasonable exercise of rights granted to it under this Agreement. Recipient may, however, disclose Confidential Information of Discloser to its employees and consultants in each case who have a specific need to know such Confidential Information and who are bound by a like obligation of confidentiality and restriction on use, or to prosecute or defend litigation. Further, either Party may disclose Confidential Information to the employees and consultants of such Party’s Affiliates who have a specific need to know such Confidential Information in order to assist Party in carrying out its rights or obligations under this Agreement and who are bound by a like obligation of confidentiality and restriction on use. Notwithstanding the foregoing, Oxford shall be entitled to disclose this Agreement to the extent required by applicable law or regulation, including, but not limited to, the public disclosure obligations of Oxford’s ultimate parent company, Oxford Immunotec Global PLC, due to its status as a publicly traded company. Prior to any public disclosure of this Agreement in satisfaction of applicable securities or other applicable laws, Oxford shall use commercially reasonable efforts to obtain and maintain confidential treatment of those portions of the Agreement that contain commercially sensitive information, including but not limited to pricing and discounts.

			

 

-7-

 

 

	 	
			6.3.

				
			Exceptions. Recipient’s obligations of non-disclosure and non-use under this Agreement will not apply to any portion of Discloser’s Confidential Information that Recipient can demonstrate, by competent proof:

			

 

	 	
			(a)

				
			is generally known to the public at the time of disclosure or becomes generally known through no wrongful act on the part of Recipient;

			

 

	 	
			(b)

				
			is in Recipient's possession at the time of disclosure other than as a result of Recipient's breach of any legal obligation;

			

 

	 	
			(c)

				
			becomes known to Recipient on a non-confidential basis through disclosure by sources other than Discloser having the legal right to disclose such Confidential Information; or

			

 

	 	
			(d)

				
			is independently developed by Recipient without reference to or reliance upon Discloser’s Confidential Information.

			

 

If Recipient is required by a governmental authority or by order of a court of competent jurisdiction to disclose any Confidential Information, Recipient will give Discloser prompt written notice of such requirement or order and Recipient will take all reasonable and lawful actions to avoid or minimize the degree of such disclosure. Recipient will cooperate reasonably with Discloser in any efforts to seek a protective order.

 

	 	
			6.4.

				
			Return. Recipient will, upon written request from Discloser, return or destroy all copies of materials containing Discloser’s Confidential Information upon termination of this Agreement for any reason whatsoever; provided, however, that Recipient may retain, for its records, one confidential copy of such information for purposes of evidencing and monitoring its ongoing compliance with this Agreement and any such copies contained in Recipient’s backup IT systems until the ordinary course deletion thereof.

			

 

-8-

 

 

	 	
			6.5.

				
			Survival of Obligations. The Parties’ obligations under this Section 6 will survive for a period of five (5) years after the expiration, cancellation or termination of this Agreement.

			

 

	
			7. 

				
			INDEMNIFICATION AND INSURANCE

			

 

	 	
			7.1.

				
			Customer Indemnity. Customer shall indemnify, defend and hold harmless Merck, its Affiliates and its and their directors, officers and employees (each a “Merck Indemnified Party”) from against all claims, actions, liabilities, losses, demands, damages, fines, penalties, costs and expenses (including without limitation reasonable attorneys’ fees) (collectively, “Losses”), arising from any Third Party claim to which any Merck Indemnified Party is or may become subject to the extent arising arise out of or are alleged or claimed to arise out of or in connection with:

			

 

	 	
			(a)

				
			any breach by Customer of any of its obligations, representations or warranties under this Agreement;

			

 

	 	
			(b)

				
			any negligent act or omission or willful misconduct by Customer, its Affiliates or its or their directors, officers, employees, agents or subcontractors;

			

 

	 	
			(c)

				
			any instruction, direction, protocol, method of manufacturing Product or Specification given by Customer or any of its Affiliates (or its or their officers, directors, employees, agents or subcontractors) to Merck or its Affiliates, which is materially followed, complied with, adopted, implemented and/or performed by Merck or its Affiliates;

			

 

	 	
			(d)

				
			the incorporation, conversion or formulation of a Product into a finished product (“Finished Product”) by Customer, its Affiliates or its or their respective subcontractors or licensees;

			

 

	 	
			(e)

				
			the labeling, marketing, distribution, offer for sale or sale of a Product or Finished Product by Customer, its Affiliates or its or their respective distributors or licensees;

			

 

	 	
			(f)

				
			the use and/or consumption of a Product or Finished Product;

			

 

	 	
			(g)

				
			the infringement by the use of a Product and/or Finished Product of any intellectual property or other proprietary rights of any Third Party; or

			

 

	 	
			(h)

				
			any violation of any applicable law or regulation by Customer, its Affiliates or its or their directors, officers, employees, agents or subcontractors;

			

 

provided, however, that Customer shall have no obligation to indemnify, defend or hold harmless the Merck Indemnified Parties for any Losses to the extent that such Losses were caused by the negligence or willful misconduct of any Merck Indemnified Party.

 

-9-

 

 

	 	
			7.2.

				
			Merck Indemnity. Merck shall indemnify, defend and hold harmless Merck, its Affiliates and its and their directors, officers and employees (each a “Customer Indemnified Party”) from against all Losses arising from any Third Party claim to which any Customer Indemnified Party is or may become subject insofar as they are based upon, arise out of or are alleged or claimed to arise out of or in connection with:

			

 

	 	
			(a)

				
			any breach by Merck of any of its obligations, representations or warranties under this Agreement;

			

 

	 	
			(b)

				
			any negligent act or omission or willful misconduct by Merck, its Affiliates or its or their directors, officers, employees, agents or subcontractors;

			

 

	 	
			(c)

				
			the infringement by the production or sale of a Product of any intellectual property or other proprietary rights of any Third Party; or

			

 

	 	
			(d)

				
			any violation of any applicable law or regulation by Merck, its Affiliates or its or their directors, officers, employees, agents or subcontractors;

			

 

provided, however, that Merck shall have no obligation to indemnify, defend or hold harmless the Customer Indemnified Parties for any Losses to the extent that such Losses were caused by the negligence or willful misconduct of any Customer Indemnified Party.

 

	 	
			7.3.

				
			Indemnification Procedures. The Party being indemnified (the “Indemnified Party”) will promptly notify the other Party (the “Indemnifying Party”) in writing within thirty (30) days after learning of any claim for which the Indemnified Party wishes to seek indemnification pursuant to Section 7.1 or Section 7.2 as the case may be. The Indemnifying Party will have the right, but not the obligation, to assume the defense of such liability with counsel satisfactory to the Indemnifying Party. If the Indemnifying Party assumes such defense, the Indemnifying Party will have the sole right to control the defense and/or settlement or other disposition of any liability, and the indemnification provisions of Section 7.1 or Section 7.2 as the case may be will not apply to amounts paid in connection with any liability if such payments are made without the consent of the Indemnifying Party; provided, that, that the Indemnified Party will have the right to retain its own counsel at its own expense but the Indemnifying Party will have final decision-making authority regarding all matters relating to such defense. The failure by the Indemnified Party to deliver notice to the Indemnifying Party in accordance with the first sentence of this Section 7.3, will relieve the Indemnifying Party of liability to the Indemnified Party under Section 7.1 or Section 7.2 as the case may be, only to the extent such delay prejudiced the ability of the Indemnifying Party to conduct such defense. At the Indemnifying Party’s request, the Indemnified Party and its directors, officers, employees and contractors will cooperate reasonably with the Indemnifying Party and its legal representatives, at the Indemnifying Party’s expense, in the investigation of any liability covered by the indemnification provisions in Section 7.1 or Section 7.2 as the case may be and will provide full information with respect to such liability.

			

 

-10-

 

 

	 	
			7.4.

				
			Customer Insurance. Without limiting its liability under this Agreement, during the Term of this Agreement, Customer shall obtain and maintain commercial general liability and product liability insurance with limits of not less than [***] Dollars ($[***]) per occurrence for general liability and product liability. Customer, promptly upon Merck’s request, shall furnish Merck with certificates of insurance evidencing such insurance coverage.

			

 

	 	
			7.5.

				
			Merck Insurance. Merck shall maintain adequate commercial general liability and product liability insurance in such amounts and with such scope of coverage as is customary in the life sciences industry with regard to the manufacture and sale of the Products. Merck, promptly upon Customer’s request, shall furnish Customer with certificates of insurance evidencing such insurance coverage.

			

 

	
			8. 

				
			REPRESENTATIONS AND WARRANTIES

			

 

	 	
			8.1.

				
			Product Warranty.

			

 

	 	
			(A)

				
			Product Warranty. Merck warrants that each Product furnished under this Agreement will conform to its Specifications for the Warranty Period (the “Product Warranty”). All Product Warranty claims must be filed in writing with Merck within the applicable Warranty Period. The duration of Merck’s Product Warranty is individual Product-specific for each Product furnished under this Agreement (the “Warranty Period”). The Warranty Period begins on the date of shipment of the Product by Merck and expires on the earliest of: (i) one (1) year from the date of shipment; or (ii) any retest date, expiration date or shelf life date printed on the Product label, packaging or certificate of analysis.

			

 

	 	
			(B)

				
			Conditions. The validity of Merck’s Product Warranty is subject to the following conditions: the Product must be installed, used, handled, maintained, stored and shipped (as applicable) in accordance with (i) all use restrictions, label licenses, instructions, recommendations and warnings that are set forth in this Agreement, in any other related agreement or document, on any Product label or packaging, or in Product literature furnished to Customer and (ii) all applicable laws and regulations.

			

 

-11-

 

 

	 	
			(C)

				
			Exclusions. The Product Warranty will not apply and Merck will have no liability under any representation or warranty with respect to: (i) any failure to comply with the conditions set forth in Section 8.1(B) above, (ii) any contamination of, or damage to, the Product after delivery of the Product by Merck; (iii) any modification, repair or enhancement of the Product by Customer or any Third Party without Merck’s prior written consent; and (iv) any Product for which payment has not been made in full to Merck.

			

 

	 	
			(D)

				
			Remedy. In the event of a valid and timely claim for breach of Product Warranty pursuant to Section 8.1(A) above, Merck’s sole obligation and Customer’s exclusive remedy will be for Merck, at its sole expense and option, to repair, rework or replace the applicable Product or part thereof, at no charge to Customer. If after exercising commercially reasonable efforts, Merck is unable to repair, rework or replace the Product or part, then Merck will credit to Customer all monies paid to Merck for such applicable Product or part. This section shall not be construed to limit Merck’s obligations pursuant to this Agreement (or any breach thereof), including Merck’s duty to indemnify Oxford.

			

 

	 	
			(E)

				
			Warranty Disclaimer. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND WHATSOEVER, EITHER EXPRESS OR IMPLIED, WRITTEN OR ORAL, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY, WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE, OR WARRANTY OF NON-INFRINGEMENT, WHETHER ARISING BY LAW, COURSE OF DEALING, COURSE OF PERFORMANCE, USAGE OF TRADE OR OTHERWISE, ALL OF WHICH ARE EXPRESSLY DISCLAIMED. Customer is solely responsible for determining the suitability of the use of any Product in its production processes.

			

 

	 	
			8.2.

				
			Compliance with Laws. Merck represents and warrants that the Products comply with all applicable federal, state and local laws and regulations and that Merck has obtained all necessary permits, licenses and certifications for providing Products hereunder.

			

 

	 	
			8.3.

				
			Intellectual Property. Merck represents and warrants that the production and sale of the Products do not infringe any patent, copyright, trademark or other proprietary rights of any Third Party except to the extent the claim of infringement arises from the modification or negligent use of the Products by Oxford.

			

 

-12-

 

 

	 	
			8.4.

				
			No Debarment. Merck represents and warrants that neither it nor, to its knowledge, any of its employees involved in manufacturing the Products as of the Effective Date (i) is currently excluded, debarred or otherwise ineligible to participate in US federal health care programs as defined in 42 U.S.C. § I 320a-7b(t) (the “Federal healthcare programs”); or (ii) to its knowledge has been convicted of a criminal offense related to the provision of healthcare items or services that could result in being excluded, debarred or otherwise declared ineligible to participate in the Federal healthcare programs; or (iii) to its knowledge, is under investigation or otherwise aware of any circumstances which may reasonably result in Merck being excluded from participation in the Federal healthcare programs.

			

 

	 	
			8.5.

				
			Limitation of Liability. NOTWITHSTANDING ANYTHING IN THIS AGREEMENT OR IN ANY PURCHASE ORDER (OR IN ANY RELATED AGREEMENT OR DOCUMENT) TO THE CONTRARY, NEITHER PARTY SHALL be liable UNDER ANY LEGAL THEORY (WHETHER TORT, CONTRACT OR OTHERWISE) for special, incidental, consequential, punitive OR ANY OTHER INDIRECT DAMAGE OR LOSS (INCLUDING, WITHOUT LIMITATION, LOST PROFITS) SUSTAINED BY THE OTHER PARTY OR ANY OTHER PERSON OR ENTITY arising out of OR RELATED TO this Agreement OR the UNDERLYING PRODUCTS, regardless of any notice of such damages. FOR PURPOSES OF THIS WAIVER, ANY LIABILITY INCURRED BY EITHER PARTY AS A RESULT OF ANY THIRD-PARTY CLAIM IS NOT CONSIDERED AN INDIRECT DAMAGE. NOTWITHSTANDING ANYTHING IN THIS AGREEMENT OR IN ANY PURCHASE ORDER (OR IN ANY RELATED AGREEMENT OR DOCUMENT) TO THE CONTRARY, under no circumstances SHALL MERCK’S aggregate liability for all claims arising out of or RELATED TO A PRODUCT PURCHASED UNDER THIS AGREEMENT exceed the amount actually received by MERCK from CUSTOMER for SUCH Product. All claims must be brought within one (1) year of SHIPMENT of the applicable Product, regardless of their nature. IN NO EVENT SHALL MERCK BE LIABLE FOR any LOSS OR DAMAGE TO CUSTOMER’S IN-PROCESS COMMERCIAL PRODUCTS.

			

 

	 	
			8.6.

				
			Compliance with Medical Device Legal Requirements. Customer acknowledges that the Products have not been tested by Merck for safety and efficacy in food, drug, medical device, cosmetic, commercial or any other use, unless otherwise explicitly stated in Product data or Product documentation provided by Merck. Customer will properly test, use, manufacture and market all Products purchased from Merck and/or materials produced with Products purchased from Merck in compliance with all applicable laws and regulations and obtain any necessary intellectual property permission for its use of the Product. Oxford shall comply with all laws and regulations of any nation regulating the marketing and sale of medical devices, applicable to Oxford’s use and sale of the Products, and agrees to assume full responsibility for the conduct of all Products recalls. Merck shall provide reasonable cooperation to Oxford’s regulatory compliance efforts with respect to the Products.

			

 

-13-

 

 

	
			9. 

				
			TERM AND TERMINATION

			

 

	 	
			9.1.

				
			Term. This Agreement will be effective commencing on the Effective Date and will, unless terminated in accordance with section 9.2, continue in full force and effect for a period of five (5) years from the Effective Date (the “Term”).

			

 

	 	
			9.2.

				
			Termination. Either Party may terminate this Agreement at any time upon at least twelve (12) months’ written notice to the other Party (“Termination for Convenience”). In the event of a Termination for Convenience by Merck, Merck shall provide Customer with the opportunity to continue to purchase Product under the terms and conditions of this Agreement for up to twelve (12) months after the actual termination date, but in no event shall Customer be permitted to purchase Product under the terms of this Agreement after the Term. If either Party breaches any material agreement, condition or covenant of this Agreement, and (i) such breach is not remedied within thirty (30) days after receipt by the breaching Party of a notice thereof from the non-breaching Party, or (ii) for any breach other than a payment breach by Customer, steps to remedy such breach have not been initiated to the non-breaching Party’s reasonable satisfaction within thirty (30) days after receipt by the breaching Party of a notice thereof from the non-breaching Party, the non-breaching Party may terminate this Agreement by written notice to the breaching Party.

			

 

	 	
			9.3.

				
			Effect of Termination. Expiration or termination of this Agreement will not affect the liability of either Party for claims or obligations that arose prior to the effective date of such expiration or termination. Without limiting the generality of the foregoing, upon expiration or termination of this Agreement for any reason, unless the Parties mutually agree otherwise or Merck elects to cancel such Purchase Orders in accordance with this Section 9.3, Customer will remain liable to purchase, and Merck will remain liable to sell and deliver, all Products covered by outstanding Purchase Orders that were accepted by Merck prior to the effective date of expiration or termination. If termination occurs as the result of Customer’s material breach of this Agreement, Merck may, in its sole discretion, elect to terminate any outstanding Purchase Orders that were accepted by Merck prior to the effective date of termination by providing notice to Customer of such cancellation along with Merck’s notice of termination for such breach. The provisions of Sections 3.1, 3.2, 3.3, 4.2(c), 4.3, 5, 6, 7, 8, 9.3, 10 and 11 will survive any expiration or termination of this Agreement.

			

 

-14-

 

 

	
			10. 

				
			EXPORT COMPLIANCE

			

 

Compliance with Laws. Customer will comply with all applicable restrictions imposed by the United States of America and all other relevant countries or jurisdictions upon the export of the Products pursuant to the Export Administration Act of 1979, 93 Statutes at Large, Section 503, et. seq., as from time to time amended, or any successor act and all regulations promulgated thereunder and all laws and regulations covering the same subject matter in all other relevant countries or jurisdictions.

 

	
			11. 

				
			MISCELLANEOUS

			

 

	 	
			11.1.

				
			Independent Contractors. The Parties are and will remain independent contractors and nothing contained in this Agreement will be construed to place the Parties in the relationship of employer and employee, partners, principal and agent, or joint ventures. Neither Party will have the power to bind or obligate the other Party nor will either Party hold itself out as having such authority.

			

 

	 	
			11.2.

				
			Publicity. Neither Party will make commitments nor disbursements, incur obligations or place any advertising, public relations or promotional material for the other Party and/or its Affiliates. Neither Party will disseminate any material of any kind using the name of such other Party and/or its affiliates or using their trademarks, without the prior written approval of an authorized representative of such other Party.

			

 

	 	
			11.3.

				
			Notices. Except as set forth in Section 4.2, any notice required or permitted to be given under this Agreement will be in writing, will specifically refer to this Agreement and will be deemed to have been sufficiently given for all purposes upon receipt if delivered (a) by first class certified or registered mail, postage prepaid, (b) express courier delivery service or (c) personally. Unless otherwise specified in writing, the notice addresses of the Parties will be as described below.

			

 

	 	If to Merck:	Millipore (U.K.) Ltd.
	 	 	Attn: Applied Sales
	 	 	Suite 21, Building 6, Croxley Green Business Park
	 	 	Watford
	 	 	Hertfordshire WD18 8YH
	 	 	UK

 

-15-

 

 

	 	With a copy to:	EMD Millipore Corporation
	 	 	Attn: Legal Department
	 	 	400 Summit Drive
	 	 	Burlington, MA 01803
	 	 	USA
	 	 	 
	 	 	 
	 	If to Customer:	Oxford Immunotec Ltd.
	 	 	Attn: Chief Executive Officer
	 	 	94C Innovation Drive, Milton Park
	 	 	Abingdon
	 	 	Oxfordshire, OX14 4RZ
	 	 	UK

 

	 	
			11.4.

				
			Governing Law. This Agreement will in all events and for all purposes be governed by, and construed in accordance with, the laws of the Commonwealth of Massachusetts without regard to any choice of law principle that would dictate the application of the law of another jurisdiction. The Parties agree that the provisions of the 1980 United Nations Convention on Contracts for the International Sale of Goods and the 1974 Convention on the Limitation Period in the International Sale of Goods, as amended by that certain Protocol adopted in Vienna on April 11, 1980, will not apply to this Agreement, and are hereby expressly excluded. The Parties consent to the exclusive jurisdiction of the state and federal courts located in Boston, Massachusetts for the enforcement of the terms of this Agreement and the entry of judgment on any award rendered under this Agreement.

			

 

	 	
			11.5.

				
			Severability. Each provision in this Agreement is independent and severable from the others, and no provision will be rendered unenforceable because any other provision may be invalid or unenforceable in whole or in part. If the scope of any restrictive provision in this Agreement is too broad to permit enforcement to its full extent, then such restriction will be reformed to the maximum extent permitted by law.

			

 

	 	
			11.6.

				
			Force Majeure. Each Party will be excused from default or delay in the performance of its obligations hereunder (other than the obligation to make payments of money) if and to the extent that such default or delay is caused by an act of nature (e.g., flood, earthquake or storm), act of war, insurrection, civil commotion, riot, destruction of facilities or materials, fire, explosion, labor disturbance or strike, the laws or regulations of any government, regulatory or judicial authority, embargo, shortage of raw materials, equipment failure, failure of public utilities or common carriers, and any other causes beyond the reasonable control of the applicable Party (each, a “Force Majeure Event”). The Party affected by a Force Majeure Event (or Merck in the case of any Force Majeure Event affecting any relevant Merck Affiliate or subcontractor) will promptly notify the other Party, explaining the nature, details and expected duration thereof. Such Party will also notify the other Party from time to time as to when the affected Party (or relevant Merck Affiliate or subcontractor as the case may be) reasonably expects to resume performance in whole or in part of its obligations under this Agreement, and to notify the other Party of the cessation of any such event. A Party affected by a Force Majeure Event will use commercially reasonable efforts to remedy, remove, or mitigate such event and the effects thereof with all reasonable dispatch. Upon termination of the Force Majeure Event, the performance of any suspended obligation or duty will promptly recommence. If the Force Majeure Event persists for more than six (6) months, Merck may terminate this Agreement by written notice to Customer.

			

 

-16-

 

 

	 	
			11.7.

				
			Assignment. Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written consent of the other Party, except either Party may make such an assignment or transfer without the other Party’s consent (a) to an Affiliate of a Party, or (b) to the successor to all or substantially all of the business or assets of a Party to which this Agreement relates (whether by merger, sale of stock, sale of assets or other transaction). Any permitted successor or assignee of rights and/or obligations hereunder will, in a writing to the other Party, expressly assume performance of such rights and/or obligations. Any assignment or attempted assignment by either Party in violation of the terms of this Section 11.7 will be null and void.

			

 

	 	
			11.8.

				
			Waiver. The failure of either Party to take action as a result of a breach of this Agreement by the other Party will constitute neither a waiver of the particular breach involved nor a waiver of either Party’s right to enforce any or all provisions of this Agreement through any remedy granted by law or this Agreement.

			

 

	 	
			11.9.

				
			Entire Understanding. This Agreement, including all Exhibits, which are incorporated into this Agreement by this reference, contains the entire understanding of the Parties with respect to its subject matter, supersedes any prior or contemporaneous written or oral communications, statements or agreements between the Parties relating to such subject matter, and may only be modified or altered in writing signed by authorized representatives of both Parties.

			

 

	 	
			11.10.

				
			Titles and Headings. The titles and headings of each section and paragraph of this Agreement are for reference only and will not affect the construction or interpretation of any provision of this Agreement.

			

 

	 	
			11.11.

				
			Third Party Beneficiaries. This Agreement is for the benefit of the Parties hereto and not for any other person except as may be specifically agreed to in writing by the Parties.

			

 

-17-

 

 

	 	
			11.12.

				
			Counterparts. This Agreement may be executed in any number of counterparts, each of which will be an original and all of which together will constitute one and the same document binding on all Parties hereto.

			

 

	 	
			11.13.

				
			Electronic Signatures. The Parties agree that electronic signatures (including but not limited to Docusign® or a comparable format) of this Agreement are intended to authenticate this Agreement and shall have the same force and effect as manual signatures.

			

 

 

[The remainder of this page is left blank intentionally.]

 

-18-

 

 

IN WITNESS WHEREOF, the Parties hereto, each by a duly authorized officer, have entered into this Agreement as of the date first set forth above.

 

 

 

	OXFORD IMMUNOTEC LIMITED	MILLIPORE (U.K.) LTD.	 
	 	 	 	 	 	 	 
	By:	/s/: A.P. Gaskell	 	By:	/s/: Victor Mark Jackson	 	/s/: Peter Biro
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	Name:	Peter Gaskell	 	Name:	Victor Mark Jackson	 	P. Biro
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	Title:	VP, Operations	 	Title:	Director	 	Director
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	Date:	07 Jan 2019	 	Date:	21st Dec 2018	 	21/21/18

 

 

 

-19-

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

 

 

EXHIBIT A

 

[***]

 

 

 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

 

 

EXHIBIT B

 

[***]ex_136263.htm

Exhibit 10.13

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

AMENDED AND RESTATED SUPPLY AND RESELLER AGREEMENT

 

This Amended and Restated Supply and Reseller Agreement (the "AGREEMENT") is by and between LIFE TECHNOLOGIES CORPORATION ("LTC"), a Delaware corporation, with a principal business address at 29851 Willow Creek Road, Eugene, Oregon 97402 and Oxford Immunotec, Ltd. ("OI"), a company incorporated under the laws of England and Wales, with a principal business address at 94C Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, U.K., and is effective as of January 1, 2019 (the "EFFECTIVE DATE").

 

 

ARTICLE 1. BACKGROUND RECITALS

	
			1.1

				
			LTC is experienced in the manufacture and supply of AIM V® Media.

			

 

	
			1.2

				
			OI is experienced in the development and marketing of in vitro diagnostic tests for the diagnosis of tuberculosis and other diseases.

			

 

	
			1.3

				
			LTC and OI (each a "Party", jointly the "Parties") previously entered into a Supply and Reseller Agreement, effective August 12, 2013, as amended on March 1, 2014, July 26, 2016, and February 16, 2017 (collectively, the “Original Agreement”), pursuant to which LTC provided OI with certain materials that are AIM V® media products for resale and for use with OI in vitro diagnostic tests for the diagnosis of tuberculosis and other diseases under the terms and conditions set forth in the Original Agreement.

			

 

	
			1.4

				
			LTC and OI now wish to amend and restate the Original Agreement in its entirety under the terms and conditions set forth hereunder.

			

 

	
			1.5

				
			Capitalized words and phrases are defined, for purposes of this AGREEMENT, where they first appear or as set forth in Article 2.

			

 

	
			1.6

				
			LTC and OI, in consideration of the premises and of the mutual covenants and agreements contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, agree to the terms and conditions herein.

			

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 1 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

ARTICLE 2. DEFINITIONS

For purposes of this AGREEMENT, the following definitions shall apply:

 

	
			2.1

				
			"AFFILIATE" means with respect to a referenced entity, any entity that CONTROLS, is CONTROLLED by, or is under common CONTROL with the referenced entity, but only so long as such CONTROL exists.

			

 

	
			2.2

				
			"AUTHORIZED LTC AFFILIATES" means LTC, or an AFFILIATE of LTC that is specifically authorized to supply LTC PRODUCTS to OI or OI AFFILIATES under this AGREEMENT. The AUTHORIZED LTC AFFILIATES under this AGREEMENT as of the EFFECTIVE DATE are listed in Exhibit A (AUTHORIZED LTC AFFILIATES), which may be unilaterally updated by LTC in accordance with paragraph 4.1.

			

 

	
			2.3

				
			"CONFIDENTIAL INFORMATION" of a Party shall have the meaning set forth in the Confidentiality Agreement dated August 12, 2013, a copy of which is attached hereto as Exhibit C.

			

 

	
			2.4

				
			"CONTROL" means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of an entity, whether through the ownership of voting securities, voting power, or similar interests in said entity.

			

 

	
			2.5

				
			"DISTRIBUTOR" means a THIRD PARTY that has a written agreement with OI pursuant to which the THIRD PARTY is authorized to promote, market and sell OI PRODUCTS in a particular geographic area to END-USERS.

			

 

	
			2.6

				
			"EFFECTIVE DATE" is defined in the preamble of the AGREEMENT.

			

 

 

	
			2.7

				
			“ELISPOT assay” means Enzyme-Linked Immunosorbent SPOT assay.

			

 

 

	
			2.8

				
			"END-USER" means the ultimate purchaser of an OI PRODUCT, whose use consumes or destroys the commercial utility of such OI PRODUCT, or after which use any remaining OI PRODUCT is discarded.

			

 

 

	OI.LTC.Supply Agreement	Page 2 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

 

	
			2.9

				
			"FIELD OF USE" means use related to the performance of ELISPOT assays for human in vitro diagnostic applications.

			

 

	
			2.10

				
			"LTC TRADEMARK RIGHTS" means the trademarks listed in Exhibit B (LTC PROPRIETARY RIGHTS), whether or not such trademarks are registered with the US Patent and Trademark Office or other governmental body.

			
	
			 

			 

				 

	
			2.11

				
			"LTC PRODUCT" means AIM V® media products supplied to OI or its AFFILIATES by the AUTHORIZED LTC AFFILIATE under the terms of this AGREEMENT, which media products are identified in Exhibit A, which Exhibit may be modified from time to time by written agreement of the Parties.

			
	
			 

			 

				 

	
			2.12

				
			“OI PRODUCT” means (i) a product made, sold or otherwise or commercialized by or on behalf of OI relating to ELISPOT assays, in each case that includes an LTC PRODUCT as a component, or (ii) an LTC PRODUCT sold or distributed by OI or AFFILIATES as a stand-alone product intended for use with ELISPOT assays that are sold or distributed by OI or AFFILIATES.

			

 

	
			2.13

				
			“OI TESTING SERVICE" means use of LTC PRODUCT(S) or OI PRODUCT(S) to perform an ELISPOT test for fee consideration by or on behalf of OI.

			

 

	
			2.14

				
			"THIRD PARTY" means a person or entity that is not OI or LTC and is not an AFFILIATE of OI or LTC.

			

 

	
			2.15

				
			"UNIT", with respect to each LTC PRODUCT, has the meaning set forth in Exhibit A.

			

 

	
			2.16

				
			"US" means the United States of America.

			

 

	
			2.17

				
			"YEAR" means calendar year.

			

 

 

 

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 3 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

ARTICLE 3. SCOPE OF AGREEMENT

	
			3.1

				
			This AGREEMENT sets forth the terms and conditions that govern LTC’s supply of the LTC PRODUCTS, as set forth in Exhibit A (LTC PRODUCTS) to OI and its AFFILIATES. This AGREEMENT does not apply to the purchase or supply of any other materials or services, and, except as provided herein, does not apply to the grant of any intellectual property rights of LTC or its AFFILIATES.

			

 

	
			3.2

				
			Subject to all of the terms and conditions of this AGREEMENT, LTC agrees to supply, or have another AUTHORIZED LTC AFFILIATE supply OI and its AFFILIATES with LTC PRODUCTS for (a) OI's or its AFFILIATES’ use in the manufacturing of OI PRODUCTS, (b) use in OI TESTING SERVICES for the FIELD OF USE, (c) sale by OI or its AFFILIATES as a component of OI PRODUCTS, or as a stand-alone product for use in conjunction with OI PRODUCTS, in each case that are sold or offered for sale in the FIELD OF USE, and (d) research and development relating to OI PRODUCTS and OI TESTING SERVICES. Subject to all of the terms of this AGREEMENT, LTC hereby grants to OI, and OI hereby accepts from LTC, a non-exclusive license under LTC TRADEMARK RIGHTS throughout the world, without right to sublicense (except to the extent that the exercise of OI’s rights by its AFFILIATES or by DISTRIBUTORS as expressly granted in 3.3 below is deemed a sublicense), for OI and its AFFILIATES to use the LTC TRADEMARK RIGHTS to import, export, offer to sell, and sell OI PRODUCTS and OI TESTING SERVICES, as set forth in subparagraphs 3.2(b) and 3.2(c) above.

			

 

	
			3.3

				
			LTC and OI agree that OI or its AFFILIATES may sell LTC PRODUCTS in conjunction with, or as a component of, OI PRODUCTS as referenced in Section 3.2(c) above, through DISTRIBUTORS, provided that such DISTRIBUTORS sell such OI PRODUCTS only for use in the FIELD OF USE and in the same packaging as received from OI or its AFFILIATES.

			

 

	
			3.4

				
			LTC reserves all rights (i) for its AFFILIATES to sell any LTC PRODUCT or (ii) to license or transfer technology used to prepare any LTC PRODUCT to any other party or parties as it may, in its sole discretion, deem advisable, or not at all; provided, however, any such license or transfer under subsection (ii) shall not affect or otherwise impair OI’s rights under this Agreement.

			

 

	
			3.5

				
			OI acknowledges that there may be proprietary rights owned by THIRD PARTIES that may be necessary for the commercialization of OI PRODUCTS or performance of OI SERVICES, and OI agrees that i) securing access to such THIRD PARTY rights is the responsibility of OI, and ii) neither LTC nor any AFFILIATE of LTC has any responsibility or liability with respect to any such THIRD PARTY proprietary rights. This AGREEMENT confers no license or rights by implication, estoppel or otherwise under any existing or future intellectual property rights owned by or licensed to LTC or its AFFILIATES other than those LTC TRADEMARK RIGHTS expressly set forth herein, if any, regardless of whether such intellectual property rights are relevant to or useful for OI’s use of LTC PRODUCTS, including use in commercialization of OI PRODUCTS or OI SERVICES, as provided herein.

			

 

	
			3.6

				
			To the extent that the rights granted to OI are shared with one or more of its AFFILIATES pursuant to paragraph 3.2 (supply rights) hereunder, OI shall require that such AFFILIATES are bound by the limitations and obligations imposed on OI hereunder..

			

 

ARTICLE 4. SUPPLY TERMS

	
			4.1

				
			LTC PRODUCTS will be supplied to OI by the AUTHORIZED LTC AFFILIATE as identified in Exhibit A (AUTHORIZED LTC AFFILIATES), according to the location in which such LTC PRODUCTS will be supplied. LTC shall have the option to designate one or more different AUTHORIZED LTC AFFILIATES, of which OI will be notified in accordance with paragraph 17.1 (notice requirements). Each AUTHORIZED LTC AFFILIATE hereunder shall be required to follow the procedures and requirements set forth herein with respect to the supply of LTC PRODUCTS; and OI’s obligations hereunder with respect to purchases and orders of LTC PRODUCTS shall be due likewise in equal measure to each such AUTHORIZED LTC AFFILIATE.

			

 

	
			4.2

				
			LTC PRODUCTS that are the subject of this Agreement are as set forth on Exhibit A, which may be amended from time to time upon agreement of the Parties. Pricing for the LTC PRODUCTS is set forth in Exhibit A (pricing of LTC PRODUCTS).

			

 

 

	OI.LTC.Supply Agreement	Page 4 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

	
			4.3

				
			The minimum number of UNITS that OI must purchase per YEAR (Minimum Annual Purchase) and minimum number of UNITS that OI must order for a single shipment to a specified location (Minimum Shipment/Minimum Order) are set forth in Exhibit A (pricing of LTC PRODUCTS). To the extent that OI's combined purchases of LTC PRODUCTS from the respective AUTHORIZED LTC AFFILIATE in any YEAR are less than the Minimum Annual Purchase for that YEAR, OI shall pay the shortfall to the respective AUTHORIZED LTC AFFILIATE, no later than thirty (30) days following the end of the YEAR in which the Minimum Annual Purchase requirement was not met.

			

 

	
			4.4

				
			OI shall submit a 12 month written forecast to LTC on the Effective Date, specifying the estimated quantity of LTC Products which OI will require for each calendar quarter for the next YEAR. OI shall submit revised forecasts 4 times per YEAR, at least one (1) month before commencement of each calendar quarter. The volume of LTC Products specified by OI for the first calendar quarter of each 12 month forecast will be a firm order, which will be invoiced by LTC not later than 30 days after the end of the relevant calendar quarter.

			

 

	
			4.5

				
			OI acknowledges that LTC PRODUCTS that are commercialized by LTC and its AFFILIATES primarily as research reagents may not be on the US Toxic Substances Control Act (TSCA) inventory and are exempt from Pre-Manufacture Notification (PMN) requirements under TSCA, or similar regulations or government controls in other jurisdictions. Nothing in this paragraph shall require LTC or its AFFILIATES to make any regulatory filings or supply any regulatory agency with any documentation other than those required in order for OI or its AFFILIATES to supply LTC PRODUCTS as research reagents. OI shall be solely responsible for obtaining all applicable regulatory authorizations, consents and licenses, including pre-market approvals, and OI must comply and require its AFFILIATES and DISTRBUTORS to comply with all governmental requirements, including but not limited to, all applicable laws, statutes, regulations, and treaties, relating to the manufacture, pre-marketing and marketing, sale, storage, shipment, and distribution of LTC PRODUCTS/OI PRODUCTS and/or OI SERVICES by or on behalf of OI, and relating to the performance of OI’s duties and obligations under this AGREEMENT. LTC or its AFFILIATES shall provide directly to any applicable regulatory agencies any information or documentation which is reasonably requested in order for OI or its AFFILIATES to obtain and maintain certifications or regulatory approvals for the labeling, marketing, sale or distribution of the LTC PRODUCTS as contemplated by this AGREEMENT.

			

 

	
			4.6

				
			OI shall not, and shall require that its AFFILIATES and DISTRIBUTORS not, (a) knowingly export, re-export, sell, or otherwise distribute, directly or indirectly, any LTC PRODUCTS (including LTC PRODUCTS incorporated in OI PRODUCTS) to a customer or nation to which LTC could not directly obtain an export license to export, re-export, sell, or otherwise distribute the LTC PRODUCTS or OI PRODUCTS, in violation of US government regulations, including US Export Administration Regulations, found at Title 15, Part 730 et seq. of the US Code of Federal Regulations; or (b) take any action in furtherance of an unlawful order, promise, or payment to a non-US public official, in violation of the US Foreign Corrupt Practices Act (FCPA), nor take any action that would cause LTC or its AFFILIATES to be in violation of the FCPA.

			

 

Notwithstanding any other provision of this AGREEMENT, neither OI, LTC, nor any of the foregoing Parties' AFFILIATES shall be required to take or refrain from taking any action impermissible or penalized under the laws of the US or any applicable foreign jurisdiction, including without limitation the anti-boycott laws administered by the US Commerce and Treasury Departments.

 

	
			4.7

				
			LTC and each AUTHORIZED LTC AFFILIATE shall comply with all laws and regulatory requirements relating to the manufacture of the LTC PRODUCTS including, without limitation, good manufacturing practices, record keeping requirements and such other requirements that may arise in accordance with ISO 13485 (“Quality System”). LTC shall ensure that each LTC PRODUCT has been manufactured in compliance with the requirements of such Quality System, and LTC shall create and retain records relating to each batch of such LTC PRODUCTS in accordance with the requirements of such Quality System.

			

 

	
			4.8

				
			LTC and OI, and their respective AFFILIATES, shall comply with the quality provisions set out in Exhibit D.

			

 

 

	OI.LTC.Supply Agreement	Page 5 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

 

ARTICLE 5. ORDERING

	
			5.1

				
			OI shall place its orders to purchase LTC PRODUCTS in writing, according to the e- mail, fax, or mailing information specified by the respective AUTHORIZED LTC AFFILIATE. With each order, OI must provide i) contact name, address, and fax, e-mail, or telephone number, ii) shipping address, iii) billing address, iv) quantity of each LTC PRODUCT and corresponding product number applicable to this AGREEMENT and the delivery schedule of such quantity (subject to paragraph 8.1), v) purchase order number, and (vi) appropriate customer account numbers.

			

 

	
			5.2

				
			Each order to purchase LTC PRODUCTS is subject to acceptance by the respective AUTHORIZED LTC AFFILIATE, which acceptance may be accomplished by shipment of the corresponding LTC PRODUCTS within the next business day or by confirmation of the expected shipment date, as set forth in Article 8 (shipping and delivery).

			

 

	
			5.3

				
			Each accepted order shall be subject to the terms, conditions and provisions of this AGREEMENT and not to any other additional or contradictory terms printed on a purchase order or acknowledgment form.

			

 

	
			5.4

				
			After an order is accepted in accordance with paragraph 5.2, the respective AUTHORIZED LTC AFFILIATE may refuse any request for changes to such order or cancellation of such order at its sole discretion but shall make commercially reasonable efforts to accommodate the requested change or cancellation.

			

 

	
			5.5

				
			Any duplicate order will be charged to OI unless the duplicate order is marked as "confirming."

			

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 6 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

ARTICLE 6. LIMITATIONS 

	
			6.1

				
			LTC PRODUCTS shall be manufactured and packaged to meet LTC’s standard specifications as set forth in Exhibit A (specifications), which specifications are subject to change solely upon advance written notice to OI.

			
	 	 

	
			6.2

				
			LTC shall prepare a Certificate of Analysis (C of A) and Material Safety Data Sheet (MSDS) for the LTC PRODUCTS and such documents shall be included with shipments of ordered LTC PRODUCTS. OI shall be responsible for distribution of information contained in the MSDS to its employees and AFFILIATES, and if such information is legally required to accompany materials transferred by OI, to THIRD PARTIES.

			
	 	 

	
			6.3

				
			The specifications for the LTC PRODUCTS set forth in Exhibit A (specifications) of this AGREEMENT shall be used to determine conformance to the specifications of the LTC PRODUCTS supplied hereunder for acceptance purposes. OI shall be solely responsible for testing and determining the suitability of LTC PRODUCTS for use in OI PRODUCTS, and any intended use or application thereof, and for communicating the appropriate cautionary information to subsequent purchasers and users of OI PRODUCTS.

			

 

	
			6.4

				
			OI hereby acknowledges that the LTC Products are warranted for research use only and that the LTC Products have no Approvals for use in diagnostic or therapeutic procedures, or for any other use requiring compliance with any law or regulation regulating diagnostic or therapeutic products or any similar product (hereinafter collectively referred to as “regulatory laws”). OI further acknowledges that LTC Products have not been tested or validated for any particular use or purpose or for safety or effectiveness. It is OI’s responsibility to test, validate or take other actions necessary for any specific use or applications and to ensure the LTC Products meet applicable regulatory, certification, validation or other requirements. The LTC Products may not be used for any purpose that would require Approvals unless proper Approvals are obtained. OI agrees that if it elects to use, or to permit any Third Party to use, the LTC Products for a purpose that would subject LTC or the LTC Products to the jurisdiction of any regulatory laws, OI will be solely responsible for obtaining any required Approvals and otherwise ensuring that OI’s (or Third Parties to whom it provides the LTC Products) use of the LTC Products complies with such regulatory laws. OI shall defend and indemnify LTC and its Affiliates against any claims, liabilities, losses, damages or expenses, including reasonable attorneys' fees and other costs of defending any action, which they may suffer as a result of any claim relating in any way to OI’s failure to obtain any necessary Approvals or to comply with any regulatory laws.

			

 

 

 

 

 

 

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 7 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

	 	For the purposes of this Article 6 “Approvals” means all necessary clearances, approvals, registrations or other qualifications or verifications required from any regulatory agency to permit use in diagnostic or therapeutic procedures, or for any other use requiring compliance with any law or regulation regulating diagnostic products or any similar product.

 

ARTICLE 7. PRICING FOR LTC PRODUCTS

	
			7.1

				
			The pricing for OI’s or its AFFILIATES’ purchases of LTC PRODUCTS under this Agreement is set forth in Exhibit A (pricing of LTC PRODUCTS). The pricing shown on Exhibit A is exclusive of value added tax.

			
	 	 

	
			7.2

				
			As noted in Exhibit A (pricing of LTC PRODUCTS), the initial purchase price may be subject to a standard price increase set forth therein, which standard price increase shall be separate from, and/or in addition to any price change resulting from a change in the specifications for such LTC PRODUCT that is requested by OI pursuant to paragraph 6.3 (modified specifications), and which standard price changes shall be effective for any shipment that occurs after the date of implementation thereof.

			

 

 

ARTICLE 8. SHIPPING AND DELIVERY 

	
			8.1

				
			Unless the respective AUTHORIZED LTC AFFILIATE and OI agree otherwise in writing, the expected shipment date for LTC PRODUCTS shall be within sixty (60) days after acceptance of an order that is placed in accordance with Article 5 (ordering), where such order does not exceed the quantity covered by the binding element of OI’s then most recent forecast provided pursuant to paragraph 4.4 (forecasts); and within ninety (90) days after acceptance of the order, where such order is in excess of the amount forecast in the binding portion of the then most recent forecast or for volumes of LTC PRODUCT not subject to the binding element of the forecast, either of which schedules may be modified if the specifications are changed at the request of OI in accordance with paragraph 6.3.

			

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 8 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

	
			8.2

				
			After acceptance of an order, and unless stated otherwise in the order, LTC PRODUCTS shall be shipped DAP OI facility (identified in Exhibit A) (Incoterms 2010) by the AUTHORIZED LTC AFFILIATE as determined with reference to Exhibit A to OI or the designated OI AFFILIATE; provided, however, that OI or the designated OI AFFILIATE shall pay for insurance in transit.

			

 

	
			8.3

				
			The respective AUTHORIZED LTC AFFILIATE will be responsible for packaging and otherwise determining the appropriate method to preserve and protect the LTC PRODUCTS during normal and customary handling in transit and meeting its obligations and regulatory requirements. LTC reserves the right for each respective AUTHORIZED LTC AFFILIATE to make delivery in installments, each such installment to be separately invoiced (including shipping charges), if necessary to meet the obligations of this paragraph.

			

 

	
			8.4

				
			Any shipment of LTC PRODUCTS may be postponed or terminated, as required by law.

			

 

	
			8.5

				
			Following shipment of the LTC PRODUCTS, the AUTHORIZED LTC AFFILIATE shall invoice OI for such LTC PRODUCTS according to the pricing as set forth in Article 7 (pricing). OI shall pay the respective AUTHORIZED LTC AFFILIATE for such LTC PRODUCTS, including shipping charges according to paragraph 8.2, according to the manner of payment set forth in paragraph 11.1 (payment methods), within thirty (30) days after the date of the invoice. OI shall be responsible for all taxes, assessments, duties, and other governmental fees of any nature whatsoever that are levied on LTC PRODUCTS upon shipment to OI.

			

 

 

ARTICLE 9. INSPECTIONS AND RETURNS

	
			9.1

				
			Any return of LTC PRODUCTS requires written authorization from the respective AUTHORIZED LTC AFFILIATE, and a return authorization number. Any claim for shipping discrepancies or damage must be made within ten (10) days after receipt of the shipment. LTC or the AUTHORIZED LTC AFFILIATE shall promptly respond to submitted claims and replace, reship, or issue a refund to OI, if applicable, depending on the type and source of error.

			

 

 

 

 

 

 

 

 

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 9 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

 

	
			9.2

				
			Provided that LTC or the AUTHORIZED LTC AFFILIATE provides the C of A and MSDS as provided in Section 6.2, within twenty (20) business days after OI receives a shipment of LTC PRODUCTS from the respective AUTHORIZED LTC AFFILIATE, OI shall notify the respective AUTHORIZED LTC AFFILIATE of any claim of a non-conforming LTC PRODUCT, but in any event prior to any use, modification or derivitization of the LTC PRODUCT other than for testing purposes by OI or its AFFILIATES to determine conformance of the LTC PRODUCTS to the specifications set forth in Exhibit A (Specifications). The absence of any such notice within such period shall constitute acceptance of the LTC PRODUCTS by OI. Within fifteen (15) business days after OI provides any such notice, LTC shall notify OI of the disposition of the claim. If LTC confirms that an LTC PRODUCT was non-conforming when shipped, LTC or the AUTHORIZED LTC AFFILIATE shall make reasonable efforts to replace any non-conforming LTC PRODUCT within 30 days after such confirmation. If LTC determines that the LTC PRODUCTS subject to the claim were in conformance with the applicable specifications when shipped, LTC or the AUTHORIZED LTC AFFILIATE and OI shall use their reasonable commercial efforts to establish the cause of the discrepancy, and to resolve the matter. OI shall arrange for the disposal and destruction of any non-conforming LTC PRODUCTS, or at LTC’s request and expense, OI shall return the non-conforming LTC PRODUCTS to LTC or the AUTHORIZED LTC AFFILIATE.

			.

			
	 	 

	
			9.3

				
			Neither LTC nor its AFFILIATES will be responsible for any non-conformance that is due to any failure by the carrier or OI to handle or store LTC PRODUCTS as indicated on the label, specifications, or accompanying product information.

			

 

 

ARTICLE 10. TRADEMARK USE 

	
			10.1

				
			OI shall use the AIM V® trademark, according to format set forth in Exhibit A (LTC PRODUCTS), in product inserts, advertisements and sales literature (including Web based literature), and on the product labels where space permits, to identify the LTC PRODUCTS in OI PRODUCTS, and shall acknowledge LTC's ownership of the trademark when so used; and the font size and style of such trademark and dye designation and acknowledgement shall be comparable to the font size and style of the text describing the LTC PRODUCTS or OI PRODUCTS in such product inserts, advertisements and sales literature. OI shall use only displays, labels, forms, and other paper or similar products imprinted with such colors and trademarks as are prescribed from time to time by LTC (including but not limited to size, design, and color of such trademarks). At the request of LTC, OI shall provide a reasonable number of OI PRODUCTS sufficient to verify that product quality standards consistent with the AIM V® trademark have been met.

			

 

 

 

 

 

 

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 10 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

	
			10.2

				
			All uses and goodwill associated with the LTC TRADEMARK RIGHTS will inure to the benefit of LTC. OI shall not register, nor attempt to register, nor aid any AFFILIATE or THIRD PARTY in the foreign registration of any trademarks included in LTC TRADEMARK RIGHTS unless LTC has given express written approval for such registration. No right or license is granted to use the trademarks included in LTC TRADEMARK RIGHTS in connection with any materials that do not contain LTC PRODUCTS.

			

 

	
			10.3

				
			OI shall promptly notify LTC in writing of any THIRD PARTY claim made against OI, its AFFILIATES, or its DISTRIBUTORS that any LTC TRADEMARK RIGHTS used by OI, infringes any trademark or similar proprietary right of any party. LTC shall determine, in its sole discretion, an appropriate response to such claim.

			

 

	
			10.4

				
			Prosecution of a THIRD PARTY for the infringing use of trademarks licensed hereunder may be undertaken by LTC at its option. OI shall provide information reasonably requested by LTC in connection with such matters.

			

 

 

ARTICLE 11. PAYMENTS

	
			11.1

				
			LTC or the AUTHORIZED LTC AFFILIATE will invoice OI or its AFFILIATE for the LTC PRODUCTS ordered in accordance with the terms of Article 5 of this AGREEMENT. OI or its AFFILIATE shall remit payment on properly issued invoices within forty-five (45) days of the date of the invoice.

			
	 	 

	
			11.2

				
			All amounts payable under this AGREEMENT to the AUTHORIZED LTC AFFILIATE shall be in the currency of the location in which the AUTHORIZED LTC AFFILIATE is located.

			

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 11 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

	
			11.3

				
			Late charges not to exceed the maximum amount allowed by law in the jurisdiction of the affected shipment may be added to invoices not paid within the specified payment term. Where invoices for LTC PRODUCTS are not timely paid, subsequent shipments may be delayed or subject to prepayment until overdue amounts are paid.

			

 

 

ARTICLE 12. CONFIDENTIALITY

	
			12.1

				
			Each Party agrees to maintain, and require its AFFILIATES and its and their employees to maintain, CONFIDENTIAL INFORMATION in accordance with the Confidentiality Agreement attached hereto as Exhibit C.

			

 

 

ARTICLE 13. WARRANTIES

	
			13.1

				
			Each Party represents and warrants to the other that (i) it is a company or corporation duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is organized; and (ii) this AGREEMENT constitutes the legal, valid and binding obligation of such Party, enforceable against such Party in accordance with its terms.

			

 

	
			13.2

				
			OI acknowledges that the LTC PRODUCTS should be used with the same protective measures and degree of caution used with any chemical compound known to be potentially hazardous, and OI covenants that the use of LTC PRODUCTS by OI or its AFFILIATES shall be supervised by a technically qualified individual.

			

 

	
			13.3

				
			LTC covenants and warrants to OI that (a) the LTC PRODUCTS shall be in compliance with the Specifications; (b) the LTC PRODUCTS will be manufactured in accordance with applicable law; (C) LTC will convey good and valid title to the LTC PRODUCTS to OI or its AFFILIATES, free from any lien, claim, security interest or encumbrance. These warranties shall survive delivery of and payment for the LTC PRODUCTS and shall run to OI, its AFFFILIATES, successors, and assigns. LTC MAKES NO OTHER REPRESENTATION OR WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT.

			

 

 

 

 

 

 

 

 

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 12 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

 

	
			13.4

				
			In the event of a breach of the warranty in Section 13.3 above, OI or its AFFILIATES shall give LTC or the AUTHORIZED LTC AFFILIATE notice of such breach. Upon receipt of such notice, LTC or the AUTHORIZED LTC AFFILIATE shall promptly and without undue delay refund the full price paid for the affected LTC PRODUCTS.

			

 

	
			13.5

				
			OI covenants that it shall manufacture and distribute OI PRODUCTS and perform OI SERVICES using commercially reasonable standards of care and quality and no less standards of care and quality than OI uses in the manufacture of other similar products or performance of other similar services. LTC shall have the right to visit and inspect the storage facilities of OI upon reasonable notice and during normal business hours subject to approval by OI regarding timing of the visit, which approval shall not be unreasonably withheld.

			

 

 

ARTICLE 14. LIMITATION OF LIABILITIES

	
			14.1

				
			SUBJECT TO ARTICLE 14.4, NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED HEREIN, NEITHER LTC NOR ITS AFFILIATES SHALL UNDER ANY CIRCUMSTANCES, BE LIABLE TO OI OR ANY OF ITS AFFILIATES FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL OR EXEMPLARY DAMAGES OF ANY KIND, ARISING OUT OF OR RELATED TO ANY TRANSACTION CONTEMPLATED HEREUNDER, INCLUDING BUT NOT LIMITED TO LOST PROFITS OR LOSS OF BUSINESS, EVEN IF LTC OR ITS AFFILIATES ARE APPRISED OF THE LIKELIHOOD OF SUCH DAMAGES OCCURRING.

			

 

	
			14.2

				
			EXCEPT FOR THE EXPRESS WARRANTIES AND REPRESENTATIONS STATED IN THIS AGREEMENT, NEITHER LTC NOR ITS AFFILIATES MAKE ANY ADDITIONAL WARRANTIES OR REPRESENTATIONS, EXPRESS OR IMPLIED OR STATUTORY, AS TO ANY MATTER WHATSOEVER. LTC AND ITS AFFILIATES EXPRESSLY DISCLAIM ANY AND ALL IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, INCLUDING ANY PURPOSE FOR THE FIELD OF USE AND LTC AND ITS AFFILIATES EXPRESSLY DISCLAIM ANY AND ALL WARRANTIES THAT THE USE OF LTC PRODUCTS, INCLUDING THE USE OF LTC PRODUCTS IN THE MANUFACTURE OF OI PRODUCTS OR ANY COMPONENT THEREOF, OR THE USE OR TRANSFER OF SUCH OI PRODUCTS OR COMPONENTS THEREOF BY OR TO ANY AFFILIATE OR THIRD PARTY, AND/OR ANY RESULTS OBTAINED BY USING SUCH LTC PRODUCTS OR OI PRODUCTS OR COMPONENT THEREOF ARE OR WILL BE FREE FROM INFRINGEMENT OF ANY PATENT OR OTHER RIGHTS OF THIRD PARTIES; AND THIS ALLOCATION OF RISK BETWEEN THE PARTIES IS REFLECTED IN THE TERMS OF THIS AGREEMENT AND IS AN ESSENTIAL ELEMENT OF THE BARGAIN BETWEEN THE PARTIES. OI SHALL NOT HAVE THE RIGHT TO MAKE OR PASS ON, AND SHALL TAKE ALL MEASURES NECESSARY TO ENSURE THAT NEITHER IT NOR ANY OF ITS AGENTS, EMPLOYEES, AFFILIATES, OR DISTRIBUTORS, OR AGENTS OR EMPLOYEES THEREOF MAKE OR PASS ON, ANY SUCH WARRANTY OR REPRESENTATION ON BEHALF OF LTC OR ITS AFFILIATES TO ANY END-USER OR OTHER THIRD PARTY.

			

 

 

 

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 13 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

	
			14.3

				
			SUBJECT TO ARTICLE 14.4, UNDER NO CIRCUMSTANCES SHALL THE TOTAL LIABILITY OF ALL KINDS (i) OF LTC AND ITS AFFILIATES, ARISING OUT OF OR RELATED TO THIS AGREEMENT INCLUDING, BUT NOT LIMITED TO, ANY WARRANTY CLAIMS HEREUNDER, REGARDLESS OF THE FORUM AND REGARDLESS OF WHETHER ANY ACTION OR CLAIM IS BASED ON CONTRACT, TORT, OR ANY OTHER LEGAL THEORY, EXCEED THE TOTAL AMOUNT PAID BY OI COLLECTIVELY TO LTC AND ITS AFFILIATES HEREUNDER (DETERMINED AS OF THE DATE OF ANY FINAL JUDGMENT IN SUCH ACTION); (ii) OF OI AND ITS AFFILIATES, ARISING OUT OF OR RELATED TO THIS AGREEMENT INCLUDING, BUT NOT LIMITED TO, ANY WARRANTY CLAIMS HEREUNDER, REGARDLESS OF THE FORUM AND REGARDLESS OF WHETHER ANY ACTION OR CLAIM IS BASED ON CONTRACT, TORT, OR ANY OTHER LEGAL THEORY, EXCEED THE TOTAL PURCHASE PAYMENTS OBLIGATED BY OI COLLECTIVELY TO LTC AND ITS AFFILIATES HEREUNDER (DETERMINED AS OF THE DATE OF ANY FINAL JUDGMENT IN SUCH ACTION).

			

 

	
			14.4

				
			Nothing in this AGREEMENT shall limit or exclude the liability of either Party for:

			

 

	 	
			(i)

				
			death or personal injury resulting from negligence; or

			

 

	 	
			(ii)

				
			fraud or fraudulent misrepresentation; or

			

 

	 	
			(iii)

				
			the indemnities contained in Article 15; or

			

 

	 	
			(iv)

				
			the deliberate default or wilful misconduct of that Party, its employees, agents or subcontractors; or

			

 

	 	
			(v)

				
			breach of the Confidentiality Agreement.

			

 

	
			14.5

				
			IT IS EXPRESSLY UNDERSTOOD AND AGREED THAT EACH AND EVERY PROVISION OF THIS AGREEMENT WHICH PROVIDES FOR A LIMITATION OF LIABILITY, DISCLAIMER OF WARRANTIES OR EXCLUSION OF DAMAGES, IS INTENDED BY THE PARTIES TO BE SEVERABLE AND INDEPENDENT OF ANY OTHER PROVISION AND TO BE ENFORCED AS SUCH.

			

 

	
			14.6

				
			OI's exclusive remedy under this AGREEMENT with regard to the supply of LTC PRODUCTS, and the entire liability hereunder of LTC and its AFFILIATES in contract, tort, or otherwise, shall be for the respective AUTHORIZED LTC AFFILIATE to use reasonable efforts to provide replacement for any non-conforming LTC PRODUCTS, provided that notice of non-conformance is received as per paragraph 9.2 (non-conformance claims). If however, after repeated efforts, the respective AUTHORIZED LTC AFFILIATE is unable to provide LTC PRODUCTS in conformance with the specification agreed hereunder, then OI's exclusive remedy under this AGREEMENT and the entire liability hereunder of LTC and its AFFILIATES in contract, tort or otherwise is to refund the amount paid by OI for the non-conforming LTC PRODUCTS. Notwithstanding the foregoing, LTC and its AFFILIATES shall have no liability for LTC PRODUCTS that are not used for the FIELD OF USE.

			

 

	
			14.7

				
			OI shall maintain in effect product liability insurance, in an amount of at least [***], regarding the sale of OI PRODUCTS and the performance of OI SERVICES. LTC shall maintain at its own expense, product liability insurance in an amount of at least [***]covering the LTC PRODUCTS, except as incorporated into OI PRODUCTS or used in OI SERVICES.

			

 

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 14 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

ARTICLE 15. INDEMNIFICATION

	
			15.1

				
			OI shall indemnify, defend and hold harmless LTC and its AFFILIATES, and their respective directors, officers, employees, and agents ("LTC Indemnitees"), from and against any and all liabilities claimed by any THIRD PARTY and including but not limited to demands, expenses (including, without limitation, costs of investigation, attorneys and professional fees and other costs of litigation, and to the extent permitted by law, fines, penalties and forfeitures in connection with any proceedings against the LTC Indemnitees), losses or causes of action, and settlement amounts, to the extent that such claimed liabilities arise out of or relate in any way to the possession, manufacture, use, sale, transfer, distribution or other disposition of OI PRODUCTS or OI SERVICES, including any use or sale of LTC PRODUCTS whether or not in combination with other substances, in each case,by or on behalf of OI, its AFFILIATES, or its or their DISTRIBUTORS, whether based on breach of warranty, negligence, product liability, infringement, misappropriation, or otherwise, except to the extent that such claimed liabilities are the result of negligence, recklessness, or willful misconduct by LTC or its AUTHORIZED LTC AFFILIATE. OI shall defend against any such claimed liabilities at its own expense, provided that LTC promptly notifies OI on learning of such claimed liabilities and cooperates with OI in such defense.

			

 

	
			15.2

				
			LTC shall indemnify, defend and hold harmless OI and its AFFILIATES, and their respective directors, officers, employees, and agents ("OI Indemnitees"), from and against any and all liabilities claimed by any THIRD PARTY and including but not limited to demands, expenses (including, without limitation, costs of investigation, attorneys and professional fees and other costs of litigation, and to the extent permitted by law, fines, penalties and forfeitures in connection with any proceedings against the OI Indemnitees), losses or causes of action, and settlement amounts, where such claimed liabilities arise out of or relate in any way to the manufacture, sale, or transfer of LTC PRODUCTS by LTC or its AFFILIATES to OI or its AFFILIATES, whether based on breach of warranty, negligence, product liability, infringement, misappropriation, or otherwise, except to the extent that such claimed liabilities are the result of negligence, recklessness, or willful misconduct by OI or its AFFILIATES. LTC shall defend against any such claimed liabilities at its own expense, provided that OI promptly notifies LTC on learning of such claimed liabilities and cooperates with LTC in such defense.

			

 

 

 

 

 

 

 

 

 

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 15 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

ARTICLE 16. TERM AND TERMINATION

	
			16.1

				
			This AGREEMENT shall commence on the EFFECTIVE DATE and, unless terminated earlier as provided herein, all obligations of LTC or its AFFILIATES to supply LTC PRODUCTS hereunder shall expire on December 31, 2019.

			

 

	
			16.2

				
			In the event that (a) OI’s twelve-month forecast provided under Section 4.4 does not reflect any anticipated purchases of an LTC PROUDCT or (b) no purchases of an LTC PRODUCT are made for a consecutive twelve (12)-month period, either Party may terminate this AGREEMENT with respect to such LTC PRODUCT upon sixty (60) days' prior written notification to the other Party according to paragraph 17.1 (notice requirements).

			

 

	
			16.3

				
			If either OI or LTC breaches any material condition of this AGREEMENT, the aggrieved Party may give written notice of the alleged breach to the other Party. The receiving Party shall have forty-five (45) days from the date of notice to cure (the “CURE PERIOD”) the identified default or alleged breach. If the identified default or alleged breach is not cured during the CURE PERIOD, this AGREEMENT shall terminate on the expiration of the CURE PERIOD. A failure on the part of an AFFILIATE of a Party to comply with the terms of this AGREEMENT shall constitute a breach of this AGREEMENT by such Party.

			

 

	
			16.4

				
			If OI becomes insolvent or enters into liquidation (excepting liquidation of a solvent company for organizational purposes) or makes an assignment for the benefit of creditors, or if proceedings for voluntary bankruptcy are instituted on behalf of OI, or if OI is declared bankrupt or insolvent, LTC may, at its election, terminate this AGREEMENT immediately by giving written notice of termination to OI.

			

 

	
			16.5

				
			Upon any expiration or termination of the AGREEMENT, each Party shall promptly return to the providing Party, at its request, all CONFIDENTIAL INFORMATION of the providing Party, or verification by an authorized signatory of the receiving Party that all such CONFIDENTIAL INFORMATION was destroyed. However, one (1) copy may be retained in the receiving Party's legal files for purposes of record keeping.

			

 

	
			16.6

				
			Articles 12 (confidentiality), 13 (warranties), 14 (limitation of liabilities), 15 (indemnification), and 18 (dispute resolution), and paragraphs 16.5 (copy of CONFIDENTIAL INFORMATION), and this paragraph 16.6 shall survive the expiration or termination of this AGREEMENT for any reasons.

			

 

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 16 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

 

ARTICLE 17. NOTICE

	
			17.1

				
			Any notices required or permitted to be given under this AGREEMENT shall be deemed given on the date submitted in writing: (a) personally; or (b) by a letter delivered to a courier guaranteeing next day service; or (c) by facsimile or e-mail, with confirmation by prepaid first class letter sent the same day.

			

 

	If to LTC:	
			THERMO FISHER SCIENTIFIC, INC.

			Life Technologies Corporation

			5823 Van Allen Way

			Carlsbad, CA 92008

			USA

			Attention: Contract Management & Analytics (CMA)

			E-mail: LMCC@thermofisher.com

			
	 	 
	With a copy to	
			THERMO FISHER SCIENTIFIC, INC.

			Life Technologies Corporation 

			29851 Willow Creek Road

			Eugene, OR 97402-9132

			USA

			Attention: Business Development Department

			Facsimile: 541-335-0354

			
	 	 
	If to OI:	
			OXFORD IMMUNOTEC LIMITED

			94C Innovation Drive

			Milton Park, Abingdon

			Oxfordshire OX14 4RZ

			United Kingdom

			Attention: Peter Gaskell

			
	 	 
	With a copy to:	
			OXFORD IMMUNOTEC USA, INC.

			General Counsel

			700 Nickerson Road

			Suite 200

			Marlborough, MA 01752

			USA

			

 

	
			17.2

				
			Any Party may change its designated address or other contact information by notice to the other Party in the manner provided in this Article.

			

 

 

	OI.LTC.Supply Agreement	Page 17 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

 

ARTICLE 18. DISPUTE RESOLUTION

	
			18.1

				
			In the event any Party claims breach of this AGREEMENT, the Parties shall consult with each other in good faith on the most effective means to cure the breach and to achieve any necessary restitution of its consequences. This consultation shall be undertaken within a period of ten (10) days following the receipt of a written request to consult, and the consultation period shall not exceed thirty (30) days. During the consultation period, neither litigation nor arbitration may be pursued until attempts at consultative dispute resolution have been exhausted.

			

 

	
			18.2

				
			Subject to Article 18.3, any dispute arising out of or in connection with this AGREEMENT, including any question regarding its existence, validity or termination, shall be referred to and finally resolved by arbitration under the Commercial Arbitration Rules of the American Arbitration Association (“Rules”) then in effect , which Rules are deemed to be incorporated by reference into this clause. The number of arbitrators shall be one. The seat, or legal place, of arbitration shall be New York. The language to be used in the arbitral proceedings shall be English.

			

 

	
			18.3

				
			This paragraph shall not apply to, and no arbitration proceeding shall deal with, disputes relating to the issues of the scope, validity and/or enforceability of any of the intellectual property licensed to any Party hereunder. In no event shall a demand for arbitration be made after the date when the initiation of a legal or equitable proceeding based on such dispute in question would be barred by the applicable statute of limitations.

			

 

 

ARTICLE 19. MISCELLANEOUS

	
			19.1

				
			Amendments. No change, modification, extension, termination, or waiver of this AGREEMENT, or any of the provisions herein contained, shall be valid unless made in writing and signed by duly authorized representatives of the Parties hereto, except as expressly provided herein.

			

 

	
			19.2

				
			Neither Party shall assign this AGREEMENT or any of its rights or liabilities hereunder without the prior written consent of the other Party; provided, however, that either Party may assign all or any part of its rights and obligations under this AGREEMENT to an AFFILIATE or successor in the event of a merger, acquisition, change of CONTROL, reorganization or sale of substantially all of the assets of such Party.

			

 

	
			19.3

				
			Binding Effect. This AGREEMENT shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties.

			

 

	
			19.4

				
			Counterparts. This AGREEMENT may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

			

 

	
			19.5

				
			Exhibit Incorporation. All Exhibits cited herein are incorporated by reference and made a part of this AGREEMENT.

			

 

	
			19.6

				
			Force Majeure. Any failure or delay in performance by either Party to this AGREEMENT caused by an event beyond the reasonable control of such Party shall not be deemed a breach of this AGREEMENT, such causes including but not limited to: natural disasters; insurrections and other hostilities; acts of governments or government agencies; and strikes or other labor disturbances. On occurrence of any such event, the Party whose performance is affected shall promptly give written notice to the other Party in accordance with 17.1 (Notice) and its best estimate of the extent and duration of its effect. The term of this AGREEMENT shall then be suspended for a corresponding period of time. If such period of suspension lasts for a period of six (6) months, the Party not affected by such event shall be entitled to terminate this AGREEMENT by providing at least one (1)-month notice.

			

 

 

	OI.LTC.Supply Agreement	Page 18 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

	
			19.7

				
			Governing Law and Venue. This AGREEMENT and all matters connected with the performance thereof shall be governed by and construed and enforced in accordance with the laws of New York, except that any dispute with respect to infringement, validity, or enforceability of any patent or published patent application shall be governed by and construed and enforced in accordance with the laws of the jurisdiction in which such patent is issued or such patent application is published. Unless otherwise agreed between the Parties, any litigation or other dispute resolution between the Parties relating to this AGREEMENT shall take place in New York.

			

 

	
			19.8

				
			Headings. The Article and paragraph headings, and paragraph parenthetical cross-references contained herein are for the purposes of convenience of reference only and are not intended to define or limit the contents of said Articles or paragraphs.

			

 

	
			19.9

				
			Independent Contractors. Nothing in this AGREEMENT is intended nor is to be construed as to constitute the Parties as partners, joint venturers, or principal and agent with respect to this AGREEMENT. Neither Party shall have any express or implied authority to bind any other Party to any other agreement, contract, obligation or undertaking with any THIRD PARTY.

			

 

	
			19.10

				
			Interpretation. Whenever required by the context, the singular term shall include the plural, the plural term shall include the singular, and the gender of any pronoun shall include all genders. Whenever the last day for the exercise of any privilege or the discharge of any duty hereunder shall fall on a Saturday, Sunday, or national or local holiday, the Party having such privilege or duty shall have until 5:00 pm on the next succeeding business day to exercise such privilege or to discharge such duty. It is further agreed that no usage of trade or other regular practice between the Parties hereto shall be used to interpret or alter the terms of this AGREEMENT. Since the Parties have participated jointly in the negotiation and drafting of this AGREEMENT, in the event an ambiguity or question of interpretation arises, no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of authorship of any provision of this AGREEMENT.

			

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 19 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

	
			19.11

				
			Prior Agreements. This AGREEMENT together with the Exhibits hereto, sets forth the entire understanding between the Parties with respect to the matters dealt with herein and supersedes any and all prior agreements (including the Original Agreement), written or oral, previously entered into by the Parties covering the matters dealt with herein.

			

 

	
			19.12

				
			Severability. If any provision of this AGREEMENT is in violation of any law or is found to be otherwise unenforceable by a court or competent administrative body from which there is no appeal, or no appeal is taken, such provision shall be deleted and the Parties shall negotiate in good faith to substitute for any such invalid or unenforceable provision, a valid and enforceable provision that achieves to the greatest extent possible the economic, legal and commercial objectives of the invalid or unenforceable provision.

			

 

	
			19.13

				
			Waiver. No delay on the part of any Party hereto in exercising any power or right hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any power or right hereunder preclude other or further exercise thereof or the exercise of any other power or right.

			

 

Each of the undersigned represents and warrants that he is duly authorized to execute this AGREEMENT and thereby bind his respective Party and that all required approvals have been obtained for the execution of this AGREEMENT, which AGREEMENT shall be binding on the Parties as of the EFFECTIVE DATE. For purposes hereof, a facsimile of a signed copy shall have the same force and effect as an original signed AGREEMENT.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 20 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

          

	LIFE TECHNOLOGIES CORPORATION	OXFORD IMMUNOTEC LIMITED
	 	 

	By:	/s/ Deborah Day Barbara	 	By:	/s/ Peter Gaskell

 

	Name/Title:	Sr. Director, Therapeutics	 	Name/Title:	VP, Operations

 

	Date:	9 January 2018	 	Date:	20 Dec 2018

         

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 21 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

Exhibit A:

 

AUTHORIZED LTC AFFILIATES

 

For the purchase of LTC PRODUCTS that will be supplied to OI or its AFFILIATES in the US, the AUTHORIZED LTC AFFILIATE is:

 

Life Technologies Corporation

A Thermo Fisher Scientific company

3175 Staley Road

Grand Island, NY 14072

USA

 

To Order:

E-mail: CustomMedia@lifetech.com

 

For the purchase of LTC PRODUCTS that will be supplied to OI or its AFFILIATES in the UK, the AUTHORIZED LTC AFFILIATE is:

 

Life Technologies Corporation

A Thermo Fisher Scientific company

3 FountainDrive

Inchinnan Business Park

Paisley, UK

PA4 9RE

Phone: 0044 141 814 6100

E-mail: mpinquiries-orders@lifetech.com

 

 

OI FACILITY

 

	
			Oxford Immunotec Limited

				
			Oxford Immunotec Limited

				
			Oxford Immunotec USA, Inc.

			
	
			94C Innovation Drive

				
			143 Park Drive

				
			320 Norwood Park South

			
	
			Milton Park, Abingdon

				
			Milton Park, Abingdon,

				
			Norwood, MA 02062

			
	
			Oxfordshire OX14 4RZ

				
			Oxfordshire, OX14 4SE

				
			USA

			
	
			United Kingdom

				
			United Kingdom

				 

 

 

	OI.LTC.Supply Agreement	Page 22 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

LTC PRODUCTS 

 

LTC PRODUCTS that are available to be supplied under this AGREEMENT, for use as set forth in Article 3 (scope of agreement), are identified in the following table:

 

	
			LTC PRODUCT

			(name)

				
			Commercial Use Product No.

				
			UNIT Size

			
	
			AIM V® Medium 

				
			A18398DJ

				
			500 mL

			
	
			AIM V® Medium 

				
			A18398SA

				
			50 mL

			

 

PRICING OF LTC PRODUCTS1

	
			LTC PRODUCT

				
			Initial Purchase Price to OI 

				
			Minimum 

			Shipment/Minimum Order 

			(UNITS per shipment/order)2 

				
			Standard Price Change

			
	
			AIM V ® 500mL package in Gibco Boxy Bottle

				
			[***]

				
			[***]

				
			[***]

			
	
			AIM V® 50mL Custom Pkg

				
			[***]

				
			[***]

				
			[***]

			

1 Subject to the provisions of paragraph 4.1 (source of supply) and Article 7 (pricing)

2 As set forth in paragraph 4.3 (required minimums) of this AGREEMENT

 

 

Minimum Annual Purchase

 

Upon the EFFECTIVE DATE and for each YEAR during the TERM OI shall purchase from the respective AUTHORIZED LTC AFFILIATE, a Minimum Annual Purchase of LTC PRODUCTS as set forth below.

 

	
			YEAR

				
			Minimum Annual Purchase

			
	
			2019 and each subsequent YEAR that this AGREEMENT is in effect 

				
			[***]

			

1 Failure to meet these Minimum Annual Purchase amounts for a given YEAR will incur a [***] percent ([***]%) increase in the price of the LTC PRODUCT for the following YEAR. For purposes of clarification, in the event OI meets or exceeds the Minimum Annual Purchase amount for a given YEAR, the price of the LTC PRODUCT for the following YEAR shall not be subject to an increase.

 

 

 

	OI.LTC.Supply Agreement	Page 23 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

 

 

 

LABEL 

 

       

 

 

 

 

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 24 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

 

 

 

SPECIFICATIONS

 

	
			Specification

				
			Result

			
	
			Bottle Size

				
			[***]

				
			[***]

			
	
			Label

				
			[***]

				
			[***]

			
	
			Packaging/Seals

				
			[***]

				
			[***]

			
	
			Grade

				
			[***]

				
			[***]

			
	
			ALBU MAX (Bovine Serum Albumin)

				
			[***]

				
			[***]

			
	
			L-Glutamine

				
			[***]

				
			[***]

			
	
			Streptomycin Sulphate

				
			[***]

				
			[***]

			
	
			Gentamicin Sulphate

				
			[***]

				
			[***]

			
	
			pH

				
			[***]

				
			[***]

			
	
			Osmolality

				
			[***]

				
			[***]

			
	
			Sterility Testing

				
			[***]

				
			[***]

			
	
			AIM V QC Assay

				
			[***]

				
			[***]

			
	
			Endotoxin Testing

				
			[***]

				
			[***]

			
	
			Mycoplasma detection

				
			[***]

				
			[***]

			
	
			HCV Antibody Screening

				
			[***]

				
			[***]

			
	
			Hepatitis B Surface Antigen Screening

				
			[***]

				
			[***]

			
	
			HIV 1 & 2 Antibody Screening

				
			[***]

				
			[***]

			

 

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 25 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 26 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

Exhibit B:

LTC PROPRIETARY RIGHTS

 

Trademark

 

 

AIM V®

GIBCO®

 

 

Patents

Boxy Bottle Patents

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 27 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

Exhibit C:

Confidentiality Agreement (pdf attached)

 

 

CONFIDENTIALITY AGREEMENT

 

This Confidentiality Agreement ("Agreement") is entered into by and between LIFE TECHNOLOGIES CORPORATION ("LTC"), a Delaware corporation, with a principal business address at 29851 Willow Creek Road, Eugene, Oregon 97402 and Oxford lmmunotec, Ltd. ("OI"), a company incorporated under the laws of England and Wales, with a principal business address at 94C Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RY, U.K., effective as of August 12, 2013.

 

RECITALS

 

WHEREAS, LTC and OI are parties to a Supply and Distribution Agreement having an effective date of August 12, 2013 (the "Supply Agreement");

 

WHEREAS, in connection with the Supply Agreement, LTC and OI may from time to time exchange or disclose information which is confidential, proprietary or a trade secret; and

 

WHEREAS, LTC and OI wish to memorialize the terms and conditions under which such confidential, proprietary or trade secret information may be disclosed and used.

 

NOW, THEREFORE, in consideration of the foregoing, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledge and agreed, LTC and OI agree to the terms and conditions set forth herein.

 

AGREEMENT

 

1.     The parties' representatives for disclosing or receiving Confidential Information (as defined herein) respectively are:

For LTC:   Stephen Chamberlain or his designee

For OI:  Jon Watts or his designee

 

2.     "Confidential Information" means any commercial or technical data, documents, materials, procedures, and similar information that is not generally known to the public and is maintained in a confidential manner and that is disclosed under this Agreement and in connection with the Supply Agreement. For sake of clarity, Confidential Information include any information derived through research or development activities and other technology, including materials business, financial or marketing plans or information relating to the LTC PRODUCTS, OI PRODUCTS or OI OTHER PRODUCTS (as those terms are defined in the Supply Agreement). Confidential Information in tangible or written form must be conspicuously marked as such. Confidential Information in intangible or verbal form should be identified as such and then a summary of the Confidential Information provided within thirty (30) days of disclosure.

 

3.     The burdens of non-use and confidentiality on the parties to this Agreement will continue until terminated by mutual agreement of the parties.

 

 

 

 

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 28 of 35	 

 

 

 

4.     Each Party shall use the Confidential Information only for purposes relating to the obligations and duties arising under or in connection with the Supply Agreement. Neither Party will disclose the Confidential Information to any person except those employees, consultants, and subcontractors to whom it is necessary to disclose the Confidential Information and any such disclosure to consultants or subcontractors shall be made solely pursuant to a written agreement with terms at least as restrictive as those specified herein. All consultants or subcontractors who receive Confidential Information must be identified in writing to the Party who disclosed the information. The receiving Party shall protect the Confidential Information of the disclosing Party by using the same degree of care as receiving Party uses to protect its own Confidential Information, but in any event no less than a reasonable degree of care.

 

5.      The duties of confidentiality under this Agreement shall apply to any and all Confidential Information disclosed by either Party, including but not limited to, such Confidential Information disclosed during site visits, in any oral disclosure or any written document, memorandum, report, correspondence, drawing or other material, or computer-readable media, developed or prepared by a Party or any of its representatives.

 

6.      Notwithstanding any other provision of this Agreement, Confidential Information shall not include any item of information which: (a) is within the public domain prior to the time of the disclosure by a Party or thereafter becomes within the public domain other than as a result of disclosure by a Party in violation of this Agreement; (b) was, on or before the date of disclosure, in the possession of a Party, as evidenced by written records of such Party; (c) is acquired by a Party from a third party not under an obligation of confidentiality; or (d) is independently developed by a Party without use of or reference to the Confidential Information of the other Party, as evidenced by written records of such Party.

 

7.      Each Party agrees to return all Confidential Information, including materials, received from the other Party upon request except that a Party may retain in its confidential files one copy of the Confidential Information for record purposes only.

 

8.      In the event that a Party or anyone to whom it transmits the Confidential Information pursuant to this Agreement becomes legally required to disclose any such Confidential Information, such Party shall provide the other with prompt notice so that the notified Party may seek a protective order or other appropriate remedy and/or waive compliance with the provisions of this Agreement. In the event that such protective order or other remedy is not obtained, the Party subject to the legal requirement to disclose Confidential Information shall furnish only that portion of the Confidential Information that it legally required to be furnished in the opinion of such Party's counsel.

 

9.      This Agreement constitutes the entire understanding between the parties hereto with respect to the subject matter hereof and merges any and all prior agreements, understanding, and representations. The Parties expressly acknowledge and agree that the Confidentiality Agreement dated September 1, 2006 between OI and Invitrogen Corporation is merged into this Agreement and the obligations of that agreement continue unabated under this Agreement.

 

 

 

 

 

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 29 of 35	 

 

 

 

10.     The Parties acknowledge and agree that the obligations of this Agreement extend to each Party's AFFILIATES (as defined in the Supply Agreement) that purchase or supply items pursuant to the Supply Agreement.

 

 

 

 

	OXFORD IMMUNOTEC LIMITED	 	LIFE TECHNOLOGIES CORPORATION	 
	 	 	 	 
	/s/ Peter Edwardson                     20 Aug 13	 	/s/ Rolando Brawer                      Aug 15, 2013	 
	Authorized Signature                   Date	 	Authorized Signature                   Date	 
	 	 	 	 
	 	 	 	 
	Name: P. Edwardson	 	Name: Rolando Brawer	 
	 	 	 	 
	Title:   General Manager	 	Title:   Director, Outlicensing	 

 

 

 

 

 

 

Approved as to legal form,

 

/s/ Allegra J. Helfenstein

 

Authorized Signatory

Allegra J. Helfenstein

Life Technologies Corporation

 

 

 

 

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 30 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

EXHIBIT D

QUALITY AGREEMENT

 

 

The following quality provisions are agreed to by Customer and LTC and hereby incorporated into this Agreement. Any capitalized terms used in this Exhibit that are not otherwise defined shall have the meanings set forth in the Supply Agreement. The Supply Agreement shall take precedence over these quality provisions in relation to any conflicts between the Supply Agreement and these quality provisions.

 

	
			1.

				
			Quality Management System.

			

LTC will maintain a Quality Management System that complies with the current version of ISO 13485.

 

	
			2.

				
			Product Complaints.

			

 

Customer will notify LTC, in writing and in a timely manner, of any confirmed customer complaints or Medical Adverse Event Reports that implicate LTC’s processes (i.e., manufacturing, filling, and packaging/distribution).

 

LTC shall cooperate with Customer, in investigating any such complaints. LTC shall, at Customer’s request and at LTC’s cost and expense, provide Customer with reasonable assistance in gathering information concerning complaints.

 

LTC, if requested by Customer, will conduct internal investigations, record reviews, and sample evaluations as required to determine the validity of the complaint and report the results to Customer. The nature of the complaint will dictate the appropriate response time.

 

In the event LTC and the Customer cannot come to an agreement on whether the customer complaint is confirmed, a technical expert will be selected and confirmed by both parties. The decision made by the technical expert will be binding and the dissenting party agrees to bear the charges of the expert.

 

	
			3.

				
			Field Actions and Recalls.

			

 

In the event Customer is required or voluntarily decides to recall or withdraw a Customer product that potentially implicates LTC’s processes, LTC will fully cooperate with Customer in connection with such a field action, recall or withdrawal.

 

 

 

 

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 31 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

	
			4.

				
			Process Control

			

 

LTC will ensure that all processes that directly affect the quality of the Products are clearly defined and carried out under controlled conditions. LTC’s process control program must include:

 

	 	
			●

				
			Documented procedures regarding how processes are to be performed and measured.

			

	 	
			●

				
			Use of suitable equipment and environment to produce and store raw materials and products.

			

	 	
			●

				
			Documentation of changes regarding production and process controls.

			

	 	
			●

				
			Trained, qualified personnel to perform operations on the Products For example where certifications are required only certified operators are to perform these operations.

			

	 	
			●

				
			Defined criteria for workmanship standards such as representative samples, specifications or illustrations.

			

	 	
			●

				
			Validation of processes that cannot be fully verified.

			

 

	
			5.

				
			Changes to LIFE Processes or Materials

			

 

LTC shall notify Customer in writing of any significant process changes that could affect Customer’s products or quality systems prior to implementation of the proposed change. Significant process or material changes include but are not limited to, changes to the production processes, manufacturing materials, manufacturing location, outsourced product and or services or equipment associated with the Products.

 

If LTC subcontracts to third parties for products and/or services, LTC will ensure that these subcontractors are in compliance with LTC’s documented Quality Management System, including those for monitoring subcontractors.

 

If requested by Customer, LTC shall provide validation protocols and applicable results of validation activities when requesting any changes to processes or equipment for which validation requirements have been established and agreed upon.

 

Without limiting the foregoing, LTC agrees to notify Customer before implementing any change affecting the Product’s Fit, Form or Function at LTC’s location (including changes in the design, specifications, raw materials, manufacturing processes and materials, equipment used, manufacturing location, outsourcing of operations or method of producing the Products). LTC shall provide a change notification to Customer at least 3 months prior to implementing the described change. In certain circumstances, such as where the change impacts a regulatory clearance or approval, OIL may require that the implementation of the change be delayed beyond six months after obtaining OIL written approval, or that sufficient stock be held by the SUPPLIER to cover the likely duration of any re-registration process.

 

 

 

 

 

 

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 32 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

	
			6.

				
			Product Identification and Traceability

			

 

LTC will maintain a system(s) to:

 

• Protect the Products from contamination by foreign materials.

• Establish unique identification of individual product or batches from receipt through all stages of production and delivery.

• Control the segregation of the Product through all production processes.

 

	
			7.

				
			Inspection

			

 

LTC will ensure that all incoming product including raw material, whether from an outside supplier or from a Customer facility are conforming to all required Specifications. LTC will establish and maintain quality records of in-process and final inspection criteria as well as document results of inspections performed on the Products.

 

When applicable, first article layout inspections will be conducted and documented by LTC. When first article layout samples are required they will be submitted according to Customer’s site requirements.

 

	
			8.

				
			Non-Conforming Product

			

 

LTC shall establish and maintain procedures for control of non-conforming products. This includes identification of nonconformance, segregation and/or quarantine, investigation of cause, evaluation and disposition of non-conformities.

 

At the request of Customer, LTC shall perform investigations and take corrective actions.

 

	
			9.

				
			Records

			

 

LTC will maintain records for 5 years after expiry for all Products supplied to Customer. If LTC ceases business with Customer, or closes its facility, then the LTC will notify Customer in writing immediately and supply Customer all requested manufacturing and quality related documents LTC will use commercially reasonable efforts to maintain and store documents in a manner to prevent loss or deterioration.

 

Customer, its employees agents, contractors and assigns will have timely access to all manufacturing and quality records for the Products supplied to Customer, either directly or by a third party in a timely manner.

 

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 33 of 35	 

 

 

 

	
			10.

				
			FDA or Governmental Authority Inspections

			

 

In the event that the FDA, Governmental Authority, EU Notified Bodies under the IVD regulation or critical supplier audits requests an inspection of LTC’s facilities and records relative to the Products purchased under the Supply Agreement, LTC agrees to comply with such request and will notify Customer immediately of any scheduled FDA or Governmental Authority audit at LTC’s facility. LTC agrees to provide to Customer copies of any written documentation relating to an FDA or Governmental Authority inspection that impacts the Products provided to Customer. This includes any 483 findings, warning letters, or any other FDA or Governmental Authority actions.

 

	
			11.

				
			Quality Reviews

			

 

Employees and representatives of OI or OI AFFILATES shall have the right to perform, and to have third parties perform on behalf of OI, comprehensive audits of LTC’s products, processes and quality program at LTC’s facility, or at the facilities of LTC’s subcontractors, as needed and at reasonable intervals, but not more than once per YEAR, to ensure proper product quality systems are in effect and to confirm compliance with applicable quality provisions herein. Any costs incurred by such audit shall be paid by OI. LTC shall not be obligated to consent to conduct of an audit more than once per YEAR (other than for cause). Any audit shall be under LTC’s reasonable confidentiality, health and safety and security restrictions. LTC may require that audits of trade secret materials and/or methods be conducted by an independent THIRD PARTY. If corrective actions are needed, LTC agrees to provide Corrective and Preventative Action plans as required.

 

LTC shall also be entitled to send technical representatives and representatives of regulatory agencies to OI’s premises to audit and inspect the manufacture of the OI PRODUCT no more than once per YEAR (other than for cause), upon giving reasonable advance notice. Any costs incurred by such audit shall be paid by LTC.

 

	
			12.

				
			Certificates of Analysis

			

 

LTC shall issue a Certificate of Analysis for each lot supplied by LTC using the following templates.

 

[Templates Follow on Next Page]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 34 of 35	 

 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

 

 

 

 

 

 

 

 

 

 

 

 

Template C of A (A18398SA and A18398DJ)

[***]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

	OI.LTC.Supply Agreement	Page 35 of 35

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}]]